



Clinical trial results:

A Single-arm Open-label International Multi-center Study Of The Efficacy And Safety Of Sunitinib Malate (SU011248, Sutent (Registered)) In Patients With Progressive Advanced Metastatic Well-differentiated Unresectable Pancreatic Neuroendocrine Tumors

Summary

EudraCT number	2011-004363-74
Trial protocol	CZ NL HU ES BE PT PL SK EE IT
Global end of trial date	

Results information

Result version number	v1
This version publication date	26 March 2017
First version publication date	26 March 2017

Trial information

Trial identification

Sponsor protocol code	A6181202
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01525550
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	07 October 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	19 March 2016
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

To confirm sunitinib treatment effect on progression-free survival (PFS) per investigator assessment in subjects with advanced/metastatic, well-differentiated, unresectable, pancreatic neuroendocrine tumors per Response Evaluation Criteria in Solid Tumors (RECIST 1.0).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 June 2012
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 4
Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	China: 31
Country: Number of subjects enrolled	Czech Republic: 10
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Hungary: 5
Country: Number of subjects enrolled	India: 2
Country: Number of subjects enrolled	Italy: 12
Country: Number of subjects enrolled	Japan: 4
Country: Number of subjects enrolled	Norway: 6
Country: Number of subjects enrolled	Romania: 12
Country: Number of subjects enrolled	Slovakia: 1
Country: Number of subjects enrolled	South Africa: 3
Country: Number of subjects enrolled	Spain: 7
Country: Number of subjects enrolled	United States: 4
Worldwide total number of subjects	106
EEA total number of subjects	58

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	92
From 65 to 84 years	14
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study was started in 6 June 2012 and is still ongoing. Primary analysis was reported in this results disclosure.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Sunitinib: Treatment Naive Cohort

Arm description:

Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive subjects.

Arm type	Experimental
Investigational medicinal product name	Sunitinib 37.5 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Subjects received Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle.

Arm title	Sunitinib: Later-Line Cohort
------------------	------------------------------

Arm description:

Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/late-line participants (subjects who developed progressive disease on or after prior systemic therapy).

Arm type	Experimental
Investigational medicinal product name	Sunitinib 37.5 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Subjects received Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle.

Number of subjects in period 1	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort
Started	61	45
Completed	0	0
Not completed	61	45
Adverse event, serious fatal	10	19
Consent withdrawn by subject	2	-
Ongoing	45	23
Lost to follow-up	4	1
Other Unspecified	-	2

Baseline characteristics

Reporting groups

Reporting group title	Sunitinib: Treatment Naive Cohort
-----------------------	-----------------------------------

Reporting group description:

Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive subjects.

Reporting group title	Sunitinib: Later-Line Cohort
-----------------------	------------------------------

Reporting group description:

Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/late-line participants (subjects who developed progressive disease on or after prior systemic therapy).

Reporting group values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort	Total
Number of subjects	61	45	106
Age categorical Units: Subjects			
18-64 years	53	39	92
65-84 years	8	6	14
Age Continuous Units: years			
arithmetic mean	55.4	53.5	
standard deviation	± 8.9	± 9.1	-
Gender, Male/Female Units: Subjects			
Female	31	12	43
Male	30	33	63

End points

End points reporting groups

Reporting group title	Sunitinib: Treatment Naive Cohort
Reporting group description: Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naive subjects.	
Reporting group title	Sunitinib: Later-Line Cohort
Reporting group description: Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/late-line participants (subjects who developed progressive disease on or after prior systemic therapy).	

Primary: Progression-Free Survival (PFS): Investigator Assessment

End point title	Progression-Free Survival (PFS): Investigator Assessment ^[1]
End point description: Investigator assessed PFS was defined as time (in months) from date of enrollment in study to date of first documented objective tumor progression or death (due to any cause), whichever occurs first. PFS calculated as (first event date minus date of enrollment plus 1)/30.4. If progression or death was not observed, the subject was censored at date of subject's last progression-free tumor assessment prior to study cut-off date. Progression as per RECIST version 1.0 criteria was defined as: greater than or equal to (\geq) 20 percent increase in sum of longest diameter (LD) of target lesions taking as a reference smallest sum of the LD recorded since treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. FAS included all subjects who were enrolled into study regardless of whether subjects received study drug or not.	
End point type	Primary
End point timeframe: Baseline until disease progression or death due to any cause (up to 1226 days)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was reported for this endpoint.

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: months				
median (confidence interval 95%)	13.2 (7.4 to 16.8)	13 (9.2 to 20.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival (PFS): Independent Radiological Review (IRR) Assessment

End point title	Progression-Free Survival (PFS): Independent Radiological
-----------------	---

End point description:

IRR assessed PFS was defined as the time (in months) from the date of enrollment in study until the date of first documented objective tumor progression or death (due to any cause), whichever occurs first. PFS calculated as (first event date minus date of enrollment plus 1)/30.4. If progression or death was not observed, the subject was censored at the date of the subject's last progression-free tumor assessment prior to the study cut-off date. Progression as per RECIST 1.0 criteria was defined as: ≥ 20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. FAS included all subjects who were enrolled into the study regardless of whether subjects received study drug or not.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until disease progression or death due to any cause (up to 1226 days)

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: months				
median (confidence interval 95%)	11.1 (5.5 to 16.7)	9.5 (7.4 to 18.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Tumor Progression (TTP): Investigator Assessment

End point title	Time to Tumor Progression (TTP): Investigator Assessment
-----------------	--

End point description:

Investigator assessed TTP was defined as the time (in months) from the date of enrollment in study until the date of first documentation of objective tumor progression. TTP calculated as (first event date minus date of enrollment plus 1)/30.4. Progression as per RECIST 1.0 was defined as ≥ 20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. FAS included all subjects who were enrolled into the study regardless of whether they received study drug or not.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until first documented tumor progression (up to 1226 days)

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: months				
median (confidence interval 95%)	14.8 (7.5 to 16.8)	14.5 (9.2 to 20.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description:	
OS was defined as the time (in months) from date of enrollment in study to the date of death due to any cause. If death was not observed, the subject was censored at the earliest of the last date the subject was known to be alive or the study cut-off date. Here, "99999" for median and confidence interval (CI) signifies data not available (NA) due to the less number of participants who had event. FAS included all subjects who were enrolled into the study regardless of whether subjects received study drug or not.	
End point type	Secondary
End point timeframe:	
Baseline until death or study cut-off (up to 5 years)	

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: months				
median (confidence interval 95%)	99999 (28.9 to 99999)	33.8 (20.3 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Objective Response (OR): Investigator Assessment

End point title	Percentage of Subjects With Objective Response (OR): Investigator Assessment
End point description:	
Investigator assessed OR in subjects was defined as having a complete response (CR) or partial response (PR) according to RECIST 1.0 and sustained for at least 4 weeks. CR was defined as disappearance of all target and non-target lesions. PR was defined as ≥ 30 percent decrease in the sum of the LD of the target lesions taking as a reference the baseline sum LD. Percentage of subjects with investigator assessed OR were reported. FAS included all subjects who were enrolled into the study regardless of whether subjects received study drug or not.	

End point type	Secondary
End point timeframe:	
Baseline until disease progression or death due to any cause (up to 1226 days)	

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: percentage of subjects				
number (confidence interval 95%)	21.3 (11.9 to 33.7)	28.9 (16.4 to 44.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR): Investigator Assessment

End point title	Duration of Response (DOR): Investigator Assessment
End point description:	
Investigator assessed DOR was defined as time (in months) from date of first documented objective tumor response (CR or PR) that was subsequently confirmed to first documented objective tumor progression or death due to any cause, whichever occurred first according to RECIST 1.0 and sustained for at least 4 weeks, confirmed by repeat tumor assessments. CR: disappearance of all target and non-target lesions. PR: ≥ 30 percent decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD. Progression as per RECIST version 1.0 was defined as ≥ 20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. Here, "99999" for CI signifies data not available (NA) due to the less number of subjects who had event. Subset of FAS which included all subjects who had response.	
End point type	Secondary
End point timeframe:	
Baseline until disease progression or death due to any cause (up to 1226 days)	

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	13		
Units: months				
median (confidence interval 95%)	19.1 (10.1 to 99999)	14.7 (5.5 to 21.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Tumor Response (TTR): Investigator Assessment

End point title	Time to Tumor Response (TTR): Investigator Assessment
-----------------	---

End point description:

Investigator assessed TTR was defined as the time (in months) from date of enrollment in study until date of first documentation of objective tumor response (CR or PR) that was subsequently confirmed. TTR was calculated as (first response date minus the date of enrollment plus 1) divided by 30.4. As per RECIST 1.0, CR was defined as disappearance of all target and non-target lesions and PR was defined as ≥ 30 percent decrease in the sum of the LD of the target lesions taking as a reference the baseline sum LD. Subset of FAS which included all subjects who had response.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until first documented objective tumor response (up to 1226 days)

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	13		
Units: months				
median (full range (min-max))	3.8 (1 to 11.1)	3.8 (1 to 9.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Objective Response: Independent Radiological Review (IRR) Assessment

End point title	Percentage of Subjects With Objective Response: Independent Radiological Review (IRR) Assessment
-----------------	--

End point description:

IRR assessed OR in subjects was defined as having a CR or PR according to Choi criteria and sustained for at least 4 weeks. According to Choi criteria, CR was defined as disappearance of all target and non-target lesions and no new lesions. PR was defined as a decrease of ≥ 10 percent in tumor size or a decrease in tumor density (HU) of 15 percent or more on Computed tomography (CT) with no new lesions and no obvious progression of non-measurable disease. Percentage of subjects with objective response were reported in this endpoint. FAS included all subjects who were enrolled into the study regardless of whether subjects received study drug or not.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until disease progression or death due to any cause (up to 1226 days)

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: percentage of subjects				
number (confidence interval 95%)	52.5 (39.3 to 65.4)	55.6 (40 to 70.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR): Independent Radiological Review (IRR) Assessment

End point title	Duration of Response (DOR): Independent Radiological Review (IRR) Assessment
-----------------	--

End point description:

IRR assessed DOR was defined as the time (in months) from the date of first documented objective tumor response (CR or PR) that was subsequently confirmed to the first documented objective tumor progression or death due to any cause, whichever occurred first. According to Choi criteria, CR was defined as disappearance of all target and non-target lesions and no new lesions. PR was defined as a decrease of ≥ 10 percent in tumor size or a decrease in tumor density (HU) of 15 percent or more on CT with no new lesions and no obvious progression of non-measurable disease. Here, "99999" for median and CI signifies data not available (NA) due to the small number of subjects who encountered tumor progression or death. Subset of FAS which included all subjects who had response.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline until disease progression or death due to any cause (up to 1226 days)

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	25		
Units: months				
number (confidence interval 95%)	99999 (17.8 to 99999)	19.2 (15.7 to 35.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Tumor Response (TTR): Independent Radiological Review (IRR) Assessment

End point title	Time to Tumor Response (TTR): Independent Radiological Review (IRR) Assessment
-----------------	--

End point description:

IRR assessed TTR was defined as the time (in months) from date of enrollment in study until first

documentation of objective tumor response (CR or PR) that was subsequently confirmed. TTR was calculated as (first response date minus the date of enrollment plus 1) divided by 30.4. For subjects proceeding from PR to CR, the onset of PR was taken as the onset of response. According to Choi criteria, CR was defined as disappearance of all target and non-target lesions and no new lesions. PR was defined as a decrease of ≥ 10 percent in tumor size or a decrease in tumor density (HU) of 15 percent or more on CT with no new lesions and no obvious progression of non-measurable disease. Subset of FAS which included all subjects who had response.

End point type	Secondary
End point timeframe:	
Baseline until first documented objective tumor response (up to 1226 days)	

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	25		
Units: months				
median (full range (min-max))	1 (0.8 to 7.3)	1 (0.9 to 3.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Chromogranin A (CgA) Response

End point title	Percentage of Subjects With Chromogranin A (CgA) Response
End point description:	
CgA response in subjects was defined as having confirmed CgA CR or CgA PR, relative to the population with an elevated baseline CgA value in the blood. CgA CR was defined as decrease from a high baseline value of CgA in the blood to one that fell within the normal range. CgA PR was defined as a decrease of greater than or equal to 50 percent from a high baseline value of CgA. Normal baseline value of CgA in blood was 39.0 ng/mL. Confirmed responses were those that persisted for at least 4 weeks after initial documentation of response. Blood levels of CgA were assessed and percentage of subjects with CgA response were reported. FAS included all subjects who were enrolled into the study regardless of whether subjects received study drug or not.	
End point type	Secondary
End point timeframe:	
Baseline until CgA response or death due to any cause (up to 1226 days)	

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: percentage of subjects				
number (confidence interval 95%)	16.4 (9.6 to 32.5)	11.1 (4 to 25.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

End point title	Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
End point description:	
EORTC QLQ-C30: cancer-specific instrument with 30 questions to assess subject quality of life (QOL). First 28 questions used for evaluating 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, vomiting, pain) and other single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Questions assessed on 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much), high score=high level of problem. Last 2 questions used for evaluating global health status/QOL. Each question was assessed on 7-point scale (1=very poor to 7=excellent). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning. Here, "99999" for mean and standard deviation signifies data not available (NA) as none of subjects were evaluable in given group at this time point. FAS population and 'n' signifies those subjects who were evaluable at specified time point for each arm.	
End point type	Secondary
End point timeframe:	
Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, End of treatment (up to maximum duration of 1226 days)	

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: units on a scale				
arithmetic mean (standard deviation)				
Global health status: Cycle 1 (n=61,43)	71.31 (± 21.111)	66.09 (± 20.282)		
Global health status: Cycle 2 (n=56,41)	69.94 (± 19.311)	65.45 (± 20.88)		
Global health status: Cycle 3 (n=55,40)	70.3 (± 21.502)	60.83 (± 26.768)		
Global health status: Cycle 4 (n=50,38)	70 (± 21.429)	61.84 (± 25.01)		
Global health status: Cycle 5 (n=47,34)	69.15 (± 19.421)	65.93 (± 24.306)		
Global health status: Cycle 6 (n=43,31)	68.41 (± 18.053)	65.32 (± 20.31)		
Global health status: Cycle 7 (n=39,29)	68.38 (± 21.132)	61.21 (± 24.016)		
Global health status: Cycle 8 (n=37,25)	70.05 (± 17.062)	65.33 (± 20.649)		

Global health status: Cycle 9 (n=35,26)	66.9 (± 20.058)	65.71 (± 20.045)		
Global health status: Cycle 10 (n=35,23)	68.1 (± 20.561)	63.04 (± 18.434)		
Global health status: Cycle 11 (n=35,24)	63.81 (± 21.384)	66.67 (± 19.812)		
Global health status: Cycle 12 (n=35,22)	65.71 (± 22.395)	64.77 (± 22.848)		
Global health status: Cycle 13 (n=34,21)	67.89 (± 20.733)	66.67 (± 19.365)		
Global health status: Cycle 14 (n=31,19)	68.28 (± 20.797)	57.89 (± 18.937)		
Global health status: Cycle 15 (n=30,17)	66.67 (± 22.318)	64.71 (± 21.757)		
Global health status: Cycle 16 (n=27,16)	64.51 (± 21.005)	67.19 (± 17.339)		
Global health status: Cycle 17 (n=22,15)	62.5 (± 23.11)	67.78 (± 15.706)		
Global health status: Cycle 18 (n=17,14)	58.33 (± 24.826)	70.83 (± 18.125)		
Global health status: Cycle 19 (n=12,14)	54.86 (± 24.736)	66.67 (± 20.672)		
Global health status: Cycle 20 (n=11,13)	55.3 (± 25.893)	64.74 (± 17.398)		
Global health status: Cycle 21 (n=11,12)	55.3 (± 23.65)	65.28 (± 18.407)		
Global health status: Cycle 22 (n=11,11)	56.06 (± 23.889)	62.88 (± 27.224)		
Global health status: Cycle 23 (n=11,10)	56.82 (± 24.386)	59.17 (± 20.953)		
Global health status: Cycle 24 (n=10,10)	50 (± 23.57)	60.83 (± 19.265)		
Global health status: Cycle 25 (n=10,8)	51.67 (± 19.954)	61.46 (± 16.022)		
Global health status: Cycle 26 (n=7,7)	50 (± 20.972)	65.48 (± 13.968)		
Global health status: Cycle 27 (n=6,8)	41.67 (± 12.91)	61.46 (± 17.216)		
Global health status: Cycle 28 (n=7,8)	44.05 (± 20.813)	61.46 (± 16.022)		
Global health status: Cycle 29 (n=5,7)	56.67 (± 19.003)	63.1 (± 16.567)		
Global health status: Cycle 30 (n=4,7)	52.08 (± 21.916)	64.29 (± 14.996)		
Global health status: Cycle 31 (n=2,7)	58.33 (± 11.785)	60.71 (± 20.813)		
Global health status: Cycle 32 (n=3,6)	61.11 (± 19.245)	59.72 (± 15.29)		
Global health status: Cycle 33 (n=3,6)	61.11 (± 12.729)	55.56 (± 22.771)		
Global health status: Cycle 34 (n=3,6)	58.33 (± 25)	55.56 (± 20.861)		
Global health status: Cycle 35 (n=2,6)	66.67 (± 23.57)	61.11 (± 13.608)		
Global health status: Cycle 36 (n=1,5)	83.33 (± 99999)	58.33 (± 16.667)		
Global health status: Cycle 37 (n=1,4)	83.33 (± 99999)	58.33 (± 21.517)		
Global health status: Cycle 38 (n=0,4)	99999 (± 99999)	58.33 (± 21.517)		
Global health status: Cycle 39 (n=1,3)	83.33 (± 99999)	50 (± 16.667)		

Global health status: Cycle 40 (n=1,3)	83.33 (± 99999)	50 (± 16.667)		
Global health status: Cycle 41 (n=0,3)	99999 (± 99999)	50 (± 16.667)		
Global health status: Cycle 42 (n=0,2)	99999 (± 99999)	45.83 (± 5.893)		
Global health status: Cycle 43 (n=0,1)	99999 (± 99999)	50 (± 99999)		
Global health status: EOT (n=33,30)	60.1 (± 22.318)	50 (± 22.21)		
Physical Functioning: Cycle 1 (n=61,44)	90.38 (± 14.733)	86.93 (± 12.677)		
Physical Functioning: Cycle 2 (n=57,42)	89.71 (± 10.988)	86.51 (± 13.929)		
Physical Functioning: Cycle 3 (n=55,40)	88.73 (± 12.886)	85 (± 17.263)		
Physical Functioning: Cycle 4 (n=50,38)	89.07 (± 10.412)	83.68 (± 16.958)		
Physical Functioning: Cycle 5 (n=47,34)	88.23 (± 11.311)	87.06 (± 17.519)		
Physical Functioning: Cycle 6 (n=43,31)	87.91 (± 11.293)	83.44 (± 18.924)		
Physical Functioning: Cycle 7 (n=39,29)	86.24 (± 12.891)	84.14 (± 15.473)		
Physical Functioning: Cycle 8 (n=37,25)	85.23 (± 12.486)	88.27 (± 11.102)		
Physical Functioning: Cycle 9 (n=35,26)	84 (± 13.255)	87.18 (± 14.474)		
Physical Functioning: Cycle 10 (n=35,23)	86.67 (± 11.771)	87.25 (± 15.943)		
Physical Functioning: Cycle 11 (n=35,24)	84.19 (± 12.944)	90.83 (± 10.552)		
Physical Functioning: Cycle 12 (n=35,22)	84.38 (± 15.419)	88.48 (± 11.489)		
Physical Functioning: Cycle 13 (n=34,21)	87.45 (± 11.808)	89.52 (± 10.016)		
Physical Functioning: Cycle 14 (n=31,19)	86.67 (± 12.996)	86.67 (± 10.423)		
Physical Functioning: Cycle 15 (n=30,17)	85.33 (± 11.534)	89.02 (± 11.041)		
Physical Functioning: Cycle 16 (n=27,16)	83.7 (± 18.053)	89.58 (± 10.319)		
Physical Functioning: Cycle 17 (n=22,15)	82.42 (± 16.657)	88 (± 9.155)		
Physical Functioning: Cycle 18 (n=17,14)	82.35 (± 18.248)	90.95 (± 8.516)		
Physical Functioning: Cycle 19 (n=12,14)	75 (± 22.406)	89.52 (± 9.324)		
Physical Functioning: Cycle 20 (n=11,13)	74.55 (± 20.181)	89.74 (± 8.439)		
Physical Functioning: Cycle 21 (n=11,12)	75.15 (± 17.911)	90 (± 7.785)		
Physical Functioning: Cycle 22 (n=11,11)	77.58 (± 22.563)	81.82 (± 24.782)		
Physical Functioning: Cycle 23 (n=11,10)	77.73 (± 18.17)	82.67 (± 14.47)		
Physical Functioning: Cycle 24 (n=10,10)	72.67 (± 22.76)	82.67 (± 14.807)		
Physical Functioning: Cycle 25 (n=10,8)	74.67 (± 23.685)	89.17 (± 10.653)		
Physical Functioning: Cycle 26 (n=7,7)	66.67 (± 25.531)	83.81 (± 13.801)		

Physical Functioning: Cycle 27 (n=6,8)	62.22 (± 27.217)	85.83 (± 12.051)		
Physical Functioning: Cycle 28 (n=7,8)	69.52 (± 21.381)	87.5 (± 11.513)		
Physical Functioning: Cycle 29 (n=6,7)	80 (± 10.328)	83.81 (± 15.803)		
Physical Functioning: Cycle 30 (n=5,7)	84 (± 3.651)	84.76 (± 11.362)		
Physical Functioning: Cycle 31 (n=3,7)	77.78 (± 10.184)	85.71 (± 13.569)		
Physical Functioning: Cycle 32 (n=3,6)	84.44 (± 3.849)	82.22 (± 10.037)		
Physical Functioning: Cycle 33 (n=3,6)	73.33 (± 6.667)	83.33 (± 10.954)		
Physical Functioning: Cycle 34 (n=3,6)	64.44 (± 21.43)	80 (± 12.649)		
Physical Functioning: Cycle 35 (n=2,6)	70 (± 23.57)	78.89 (± 12.939)		
Physical Functioning: Cycle 36 (n=1,5)	86.67 (± 99999)	80 (± 9.428)		
Physical Functioning: Cycle 37 (n=1,4)	86.67 (± 99999)	76.67 (± 3.849)		
Physical Functioning: Cycle 38 (n=0,4)	99999 (± 99999)	75 (± 6.383)		
Physical Functioning: Cycle 39 (n=1,3)	86.67 (± 99999)	77.78 (± 3.849)		
Physical Functioning: Cycle 40 (n=1,3)	93.33 (± 99999)	71.11 (± 10.184)		
Physical Functioning: Cycle 41 (n=0,3)	99999 (± 99999)	77.78 (± 10.184)		
Physical Functioning: Cycle 42 (n=0,2)	99999 (± 99999)	80 (± 0)		
Physical Functioning: Cycle 43 (n=0,1)	99999 (± 99999)	80 (± 99999)		
Physical Functioning: EOT(n=33,30)	76.16 (± 23.454)	78 (± 19.191)		
Role Functioning: Cycle 1 (n=60,44)	88.33 (± 20.424)	85.61 (± 18.88)		
Role Functioning: Cycle 2 (n=57,42)	85.67 (± 17.089)	80.56 (± 25.214)		
Role Functioning: Cycle 3 (n=55,40)	85.15 (± 18.613)	80.83 (± 25.473)		
Role Functioning: Cycle 4 (n=50,38)	84.67 (± 17.444)	80.26 (± 23.841)		
Role Functioning: Cycle 5 (n=47,34)	85.82 (± 19.343)	82.35 (± 23.904)		
Role Functioning: Cycle 6 (n=43,31)	86.05 (± 16.639)	79.57 (± 25.353)		
Role Functioning: Cycle 7 (n=39,29)	83.33 (± 21.965)	81.03 (± 24.285)		
Role Functioning: Cycle 8 (n=37,25)	80.63 (± 19.049)	85.33 (± 16.887)		
Role Functioning: Cycle 9 (n=35,26)	76.19 (± 22.968)	80.77 (± 22.945)		
Role Functioning: Cycle 10 (n=35,23)	82.86 (± 18.737)	83.33 (± 23.028)		
Role Functioning: Cycle 11 (n=35,24)	79.52 (± 22.537)	86.11 (± 18.822)		
Role Functioning: Cycle 12 (n=35,22)	79.52 (± 20.246)	84.85 (± 19.182)		
Role Functioning: Cycle 13 (n=34,21)	82.35 (± 19.219)	84.13 (± 17.059)		

Role Functioning: Cycle 14 (n=31,19)	81.72 (\pm 20.346)	79.82 (\pm 19.704)		
Role Functioning: Cycle 15 (n=30,17)	77.22 (\pm 22.946)	77.45 (\pm 22.777)		
Role Functioning: Cycle 16 (n=27,16)	77.16 (\pm 24.956)	84.38 (\pm 15.478)		
Role Functioning: Cycle 17 (n=22,15)	74.24 (\pm 24.52)	82.22 (\pm 17.213)		
Role Functioning: Cycle 18 (n=17,14)	75.49 (\pm 28.332)	84.52 (\pm 16.621)		
Role Functioning: Cycle 19 (n=12,14)	66.67 (\pm 26.591)	79.76 (\pm 20.856)		
Role Functioning: Cycle 20 (n=11,13)	69.7 (\pm 27.707)	80.77 (\pm 19.059)		
Role Functioning: Cycle 21 (n=11,12)	68.18 (\pm 27.34)	79.17 (\pm 23.704)		
Role Functioning: Cycle 22 (n=11,11)	68.18 (\pm 29.302)	71.21 (\pm 29.899)		
Role Functioning: Cycle 23 (n=11,10)	63.64 (\pm 30.567)	71.67 (\pm 24.907)		
Role Functioning: Cycle 24 (n=10,10)	60 (\pm 27.442)	76.67 (\pm 22.498)		
Role Functioning: Cycle 25 (n=10,8)	58.33 (\pm 30.682)	77.08 (\pm 23.465)		
Role Functioning: Cycle 26 (n=7,7)	57.14 (\pm 30.211)	83.33 (\pm 16.667)		
Role Functioning: Cycle 27 (n=6,8)	58.33 (\pm 36.132)	77.08 (\pm 23.465)		
Role Functioning: Cycle 28 (n=7,8)	59.52 (\pm 18.898)	79.17 (\pm 24.801)		
Role Functioning: Cycle 29 (n=6,7)	75 (\pm 13.944)	78.57 (\pm 24.934)		
Role Functioning: Cycle 30 (n=5,7)	90 (\pm 14.907)	76.19 (\pm 25.198)		
Role Functioning: Cycle 31 (n=3,7)	83.33 (\pm 16.667)	78.57 (\pm 24.934)		
Role Functioning: Cycle 32 (n=3,6)	94.44 (\pm 9.623)	77.78 (\pm 20.184)		
Role Functioning: Cycle 33 (n=3,6)	88.89 (\pm 19.245)	72.22 (\pm 25.092)		
Role Functioning: Cycle 34 (n=3,6)	72.22 (\pm 34.694)	69.44 (\pm 30.581)		
Role Functioning: Cycle 35 (n=2,6)	75 (\pm 35.355)	72.22 (\pm 25.092)		
Role Functioning: Cycle 36 (n=1,5)	100 (\pm 99999)	73.33 (\pm 19.003)		
Role Functioning: Cycle 37 (n=1,4)	66.67 (\pm 99999)	70.83 (\pm 28.464)		
Role Functioning: Cycle 38 (n=0,4)	99999 (\pm 99999)	66.67 (\pm 27.217)		
Role Functioning: Cycle 39 (n=1,3)	100 (\pm 99999)	55.56 (\pm 19.245)		
Role Functioning: Cycle 40 (n=1,3)	100 (\pm 99999)	55.56 (\pm 9.623)		
Role Functioning: Cycle 41 (n=0,3)	99999 (\pm 99999)	55.56 (\pm 19.245)		
Role Functioning: Cycle 42 (n=0,2)	99999 (\pm 99999)	66.67 (\pm 0)		
Role Functioning: Cycle 43 (n=0,1)	99999 (\pm 99999)	66.67 (\pm 99999)		
Role Functioning: EOT (n=33,30)	70.71 (\pm 26.031)	65.56 (\pm 36.075)		

Emotional Functioning: Cycle 1 (n=61,43)	80.19 (± 18.644)	76.23 (± 18.238)		
Emotional Functioning: Cycle 2 (n=57,41)	84.31 (± 17.619)	77.64 (± 17.021)		
Emotional Functioning: Cycle 3 (n=55,40)	82.53 (± 18.792)	73.96 (± 24.401)		
Emotional Functioning: Cycle 4 (n=50,38)	82.67 (± 16.906)	77.41 (± 22.167)		
Emotional Functioning: Cycle 5 (n=47,34)	82.09 (± 18.632)	79.66 (± 21.141)		
Emotional Functioning: Cycle 6 (n=43,31)	82.17 (± 17.871)	73.92 (± 24.696)		
Emotional Functioning: Cycle 7 (n=39,29)	80.56 (± 21.059)	73.56 (± 26.075)		
Emotional Functioning: Cycle 8 (n=37,25)	80.63 (± 21.877)	76 (± 18.991)		
Emotional Functioning: Cycle 9 (n=35,26)	80.24 (± 19.812)	76.92 (± 18.304)		
Emotional Functioning: Cycle 10 (n=35,23)	81.27 (± 19.818)	76.45 (± 21.998)		
Emotional Functioning: Cycle 11 (n=35,24)	79.76 (± 19.311)	75.46 (± 20.587)		
Emotional Functioning: Cycle 12 (n=35,22)	78.1 (± 23.052)	75.76 (± 22.7)		
Emotional Functioning: Cycle 13 (n=34,21)	77.45 (± 22.429)	77.38 (± 19.211)		
Emotional Functioning: Cycle 14 (n=31,19)	78.49 (± 20.387)	75 (± 24.375)		
Emotional Functioning: Cycle 15 (n=30,17)	80 (± 21.173)	74.51 (± 23.839)		
Emotional Functioning: Cycle 16 (n=27,16)	82.1 (± 22.133)	75 (± 24.343)		
Emotional Functioning: Cycle 17 (n=22,15)	79.92 (± 23.522)	79.44 (± 19.382)		
Emotional Functioning: Cycle 18 (n=17,14)	78.92 (± 23.592)	76.19 (± 25.499)		
Emotional Functioning: Cycle 19 (n=12,14)	73.61 (± 28.611)	73.81 (± 25.288)		
Emotional Functioning: Cycle 20 (n=11,13)	71.21 (± 29.666)	78.85 (± 25.823)		
Emotional Functioning: Cycle 21 (n=11,12)	76.52 (± 28.824)	75 (± 25.624)		
Emotional Functioning: Cycle 22 (n=11,11)	75.76 (± 30.834)	78.03 (± 22.445)		
Emotional Functioning: Cycle 23 (n=11,10)	74.24 (± 30.834)	75 (± 27.778)		
Emotional Functioning: Cycle 24 (n=10,10)	71.67 (± 28.921)	76.67 (± 22.153)		
Emotional Functioning: Cycle 25 (n=10,8)	65.83 (± 33.206)	66.67 (± 29.881)		
Emotional Functioning: Cycle 26 (n=7,7)	71.43 (± 34.979)	77.38 (± 17.156)		
Emotional Functioning: Cycle 27 (n=6,8)	56.94 (± 32.667)	68.75 (± 29.124)		
Emotional Functioning: Cycle 28 (n=7,8)	65.48 (± 34.166)	68.75 (± 29.463)		
Emotional Functioning: Cycle 29 (n=5,7)	68.33 (± 29.698)	71.43 (± 31.127)		
Emotional Functioning: Cycle 30 (n=4,7)	72.92 (± 29.95)	70.24 (± 31.497)		
Emotional Functioning: Cycle 31 (n=2,7)	45.83 (± 17.678)	72.62 (± 26.227)		

Emotional Functioning: Cycle 32 (n=3,6)	69.44 (± 29.266)	69.44 (± 33.61)		
Emotional Functioning: Cycle 33 (n=3,6)	77.78 (± 19.245)	70.83 (± 27.764)		
Emotional Functioning: Cycle 34 (n=3,6)	66.67 (± 33.333)	66.67 (± 34.561)		
Emotional Functioning: Cycle 35 (n=2,6)	83.33 (± 23.57)	68.06 (± 33.918)		
Emotional Functioning: Cycle 36 (n=1,5)	100 (± 99999)	71.67 (± 31.513)		
Emotional Functioning: Cycle 37 (n=1,4)	100 (± 99999)	77.08 (± 35.6)		
Emotional Functioning: Cycle 38 (n=0,4)	99999 (± 99999)	70.83 (± 42.219)		
Emotional Functioning: Cycle 39 (n=1,3)	100 (± 99999)	63.89 (± 48.829)		
Emotional Functioning: Cycle 40(n=1,3)	100 (± 99999)	66.67 (± 38.188)		
Emotional Functioning: Cycle 41(n=0,3)	99999 (± 99999)	58.33 (± 41.667)		
Emotional Functioning: Cycle 42(n=0,2)	99999 (± 99999)	54.17 (± 64.818)		
Emotional Functioning: Cycle 43(n=0,1)	99999 (± 99999)	100 (± 99999)		
Emotional Functioning: EOT (n=33,30)	67.17 (± 23.748)	66.94 (± 27.024)		
Cognitive Functioning: Cycle 1 (n=61,43)	90.16 (± 15.329)	88.76 (± 15.31)		
Cognitive Functioning: Cycle 2 (n=57,41)	88.89 (± 15.537)	89.43 (± 13.31)		
Cognitive Functioning: Cycle 3 (n=55,40)	89.09 (± 15.119)	87.5 (± 19.882)		
Cognitive Functioning: Cycle 4 (n=50,38)	89.67 (± 12.993)	87.72 (± 15.346)		
Cognitive Functioning: Cycle 5 (n=47,34)	88.65 (± 15.583)	85.29 (± 22.385)		
Cognitive Functioning: Cycle 6 (n=43,31)	89.53 (± 15.006)	82.8 (± 25.993)		
Cognitive Functioning: Cycle 7 (n=39,29)	89.74 (± 14.618)	85.06 (± 20.091)		
Cognitive Functioning: Cycle 8 (n=37,25)	87.39 (± 13.836)	83.33 (± 21.517)		
Cognitive Functioning: Cycle 9 (n=35,26)	88.1 (± 16.455)	85.26 (± 20.181)		
Cognitive Functioning: Cycle 10 (n=35,23)	88.1 (± 13.75)	83.33 (± 21.32)		
Cognitive Functioning: Cycle 11 (n=35,24)	86.67 (± 16.068)	86.11 (± 17.492)		
Cognitive Functioning: Cycle 12 (n=35,22)	86.67 (± 13.886)	86.36 (± 18.993)		
Cognitive Functioning: Cycle 13 (n=34,21)	87.25 (± 15.922)	85.71 (± 19.211)		
Cognitive Functioning: Cycle 14 (n=31,19)	88.71 (± 13.185)	77.19 (± 22.368)		
Cognitive Functioning: Cycle 15 (n=30,17)	88.33 (± 12.495)	80.39 (± 27.154)		
Cognitive Functioning: Cycle 16 (n=27,16)	88.27 (± 12.067)	80.21 (± 24.509)		
Cognitive Functioning: Cycle 17 (n=22,15)	89.39 (± 12.112)	84.44 (± 20.38)		
Cognitive Functioning: Cycle 18 (n=17,14)	88.24 (± 14.148)	79.76 (± 24.615)		

Cognitive Functioning: Cycle 19 (n=12,14)	88.89 (± 12.975)	78.57 (± 24.832)		
Cognitive Functioning: Cycle 20 (n=11,13)	90.91 (± 11.459)	82.05 (± 24.964)		
Cognitive Functioning: Cycle 21 (n=11,12)	89.39 (± 11.237)	76.39 (± 26.071)		
Cognitive Functioning: Cycle 22 (n=11,11)	86.36 (± 12.513)	81.82 (± 20.35)		
Cognitive Functioning: Cycle 23 (n=11,10)	84.85 (± 11.677)	76.67 (± 27.442)		
Cognitive Functioning: Cycle 24 (n=10,10)	85 (± 16.574)	81.67 (± 19.954)		
Cognitive Functioning: Cycle 25 (n=10,8)	81.67 (± 18.342)	75 (± 25.198)		
Cognitive Functioning: Cycle 26(n=7,7)	85.71 (± 20.25)	85.71 (± 17.817)		
Cognitive Functioning: Cycle 27(n=6,8)	75 (± 20.412)	77.08 (± 25.099)		
Cognitive Functioning: Cycle 28(n=7,8)	76.19 (± 18.898)	72.92 (± 29.463)		
Cognitive Functioning: Cycle 29(n=5,7)	76.67 (± 14.907)	78.57 (± 26.726)		
Cognitive Functioning: Cycle 30(n=4,7)	75 (± 16.667)	76.19 (± 31.706)		
Cognitive Functioning: Cycle 31(n=2,7)	83.33 (± 23.57)	73.81 (± 31.706)		
Cognitive Functioning: Cycle 32(n=3,6)	83.33 (± 16.667)	69.44 (± 32.347)		
Cognitive Functioning: Cycle 33(n=3,6)	88.89 (± 19.245)	69.44 (± 26.701)		
Cognitive Functioning: Cycle 34(n=3,6)	77.78 (± 9.623)	66.67 (± 34.96)		
Cognitive Functioning: Cycle 35(n=2,6)	100 (± 0)	75 (± 27.386)		
Cognitive Functioning: Cycle 36(n=1,5)	100 (± 99999)	73.33 (± 34.561)		
Cognitive Functioning: Cycle 37(n=1,4)	100 (± 99999)	75 (± 39.675)		
Cognitive Functioning: Cycle 38(n=0,4)	99999 (± 99999)	70.83 (± 47.871)		
Cognitive Functioning: Cycle 39(n=1,3)	100 (± 99999)	72.22 (± 34.694)		
Cognitive Functioning: Cycle 40(n=1,3)	83.33 (± 99999)	61.11 (± 34.694)		
Cognitive Functioning: Cycle 41(n=0,3)	99999 (± 99999)	61.11 (± 41.944)		
Cognitive Functioning: Cycle 42(n=0,2)	99999 (± 99999)	50 (± 70.711)		
Cognitive Functioning: Cycle 43(n=0,1)	99999 (± 99999)	100 (± 99999)		
Cognitive Functioning: EOT (n=33,30)	83.33 (± 17.18)	78.33 (± 23.631)		
Social Functioning: Cycle 1 (n=61,43)	80.87 (± 23.734)	79.46 (± 25.675)		
Social Functioning: Cycle 2 (n=57,41)	83.04 (± 20.288)	82.93 (± 20.578)		
Social Functioning: Cycle 3 (n=55,40)	79.09 (± 23.399)	77.08 (± 26.335)		
Social Functioning: Cycle 4 (n=50,38)	81.67 (± 21.626)	79.82 (± 25.16)		
Social Functioning: Cycle 5 (n=47,34)	80.85 (± 21.697)	79.41 (± 26.291)		
Social Functioning: Cycle 6 (n=43,31)	80.23 (± 28.232)	77.42 (± 28.398)		

Social Functioning: Cycle 7 (n=39,29)	80.34 (± 22.579)	83.91 (± 27.271)		
Social Functioning: Cycle 8 (n=37,25)	78.83 (± 21.748)	80 (± 25.909)		
Social Functioning: Cycle 9 (n=35,26)	77.62 (± 24.234)	82.05 (± 23.534)		
Social Functioning: Cycle 10 (n=35,23)	81.43 (± 20.119)	76.81 (± 26.939)		
Social Functioning: Cycle 11 (n=35,24)	76.19 (± 23.321)	81.25 (± 26.151)		
Social Functioning: Cycle 12 (n=35,22)	75.71 (± 25.03)	81.82 (± 27.172)		
Social Functioning: Cycle 13 (n=34,21)	77.94 (± 25.859)	84.92 (± 21.67)		
Social Functioning: Cycle 14 (n=31,19)	81.18 (± 20.968)	79.82 (± 29.7)		
Social Functioning: Cycle 15 (n=30,17)	76.67 (± 19.865)	74.51 (± 31.797)		
Social Functioning: Cycle 16 (n=27,16)	75.93 (± 24.167)	77.08 (± 25)		
Social Functioning: Cycle 17 (n=22,15)	75 (± 25.066)	75.56 (± 25.871)		
Social Functioning: Cycle 18 (n=17,14)	76.47 (± 27.041)	82.14 (± 28.09)		
Social Functioning: Cycle 19 (n=12,14)	72.22 (± 24.958)	77.38 (± 26.64)		
Social Functioning: Cycle 20 (n=11,13)	75.76 (± 30.151)	83.33 (± 21.517)		
Social Functioning: Cycle 21 (n=11,12)	71.21 (± 28.955)	81.94 (± 26.071)		
Social Functioning: Cycle 22 (n=11,11)	69.7 (± 33.181)	75.76 (± 30.151)		
Social Functioning: Cycle 23 (n=11,10)	71.21 (± 30.814)	78.33 (± 31.476)		
Social Functioning: Cycle 24 (n=10,10)	63.33 (± 32.203)	76.67 (± 30.631)		
Social Functioning: Cycle 25 (n=10,8)	70 (± 39.126)	66.67 (± 34.503)		
Social Functioning: Cycle 26 (n=7,7)	61.9 (± 34.311)	88.1 (± 15.853)		
Social Functioning: Cycle 27 (n=6,8)	58.33 (± 32.914)	70.83 (± 33.034)		
Social Functioning: Cycle 28 (n=7,8)	73.81 (± 38.318)	77.08 (± 28.084)		
Social Functioning: Cycle 29 (n=5,7)	80 (± 18.257)	71.43 (± 34.311)		
Social Functioning: Cycle 30 (n=4,7)	75 (± 31.914)	69.05 (± 36.551)		
Social Functioning: Cycle 31 (n=2,7)	66.67 (± 47.14)	71.43 (± 35.635)		
Social Functioning: Cycle 32 (n=3,6)	77.78 (± 19.245)	66.67 (± 36.515)		
Social Functioning: Cycle 33 (n=3,6)	66.67 (± 0)	69.44 (± 30.581)		
Social Functioning: Cycle 34 (n=3,6)	66.67 (± 0)	63.89 (± 37.143)		
Social Functioning: Cycle 35 (n=2,6)	66.67 (± 23.57)	72.22 (± 37.515)		
Social Functioning: Cycle 36 (n=1,5)	100 (± 99999)	53.33 (± 36.132)		
Social Functioning: Cycle 37 (n=1,4)	66.67 (± 99999)	58.33 (± 41.944)		

Social Functioning: Cycle 38 (n=0,4)	99999 (± 99999)	66.67 (± 36.004)		
Social Functioning: Cycle 39 (n=1,3)	100 (± 99999)	44.44 (± 38.49)		
Social Functioning: Cycle 40 (n=1,3)	66.67 (± 99999)	61.11 (± 38.49)		
Social Functioning: Cycle 41 (n=0,3)	99999 (± 99999)	44.44 (± 25.459)		
Social Functioning: Cycle 42 (n=0,2)	99999 (± 99999)	41.67 (± 35.355)		
Social Functioning: Cycle 43 (n=0,1)	99999 (± 99999)	66.67 (± 99999)		
Social Functioning: EOT (n=33,30)	73.74 (± 25.355)	65 (± 29.148)		
Fatigue: Cycle 1 (n=61,44)	21.49 (± 20.374)	29.42 (± 17.835)		
Fatigue: Cycle 2 (n=57,42)	24.37 (± 17.995)	29.1 (± 19.001)		
Fatigue: Cycle 3 (n=55,40)	26.46 (± 19.303)	30.28 (± 22.644)		
Fatigue: Cycle 4 (n=50,38)	24 (± 18.424)	29.53 (± 24.133)		
Fatigue: Cycle 5 (n=47,34)	26 (± 17.069)	27.61 (± 23.865)		
Fatigue: Cycle 6 (n=43,31)	25.32 (± 17.029)	29.93 (± 25.526)		
Fatigue: Cycle 7 (n=39,29)	26.78 (± 21.284)	28.35 (± 24.232)		
Fatigue: Cycle 8 (n=37,25)	27.63 (± 17.297)	23.11 (± 18.681)		
Fatigue: Cycle 9 (n=35,26)	26.35 (± 20.182)	22.22 (± 20.608)		
Fatigue: Cycle 10 (n=35,23)	26.03 (± 19.975)	24.64 (± 23.914)		
Fatigue: Cycle 11 (n=35,24)	27.94 (± 18.548)	22.45 (± 20.624)		
Fatigue: Cycle 12 (n=35,22)	26.35 (± 20.001)	22.22 (± 23.256)		
Fatigue: Cycle 13 (n=34,21)	25.16 (± 19.012)	18.52 (± 15.045)		
Fatigue: Cycle 14 (n=31,19)	24.73 (± 19.183)	24.56 (± 20.813)		
Fatigue: Cycle 15 (n=30,17)	24.07 (± 20.443)	24.84 (± 24.066)		
Fatigue: Cycle 16 (n=27,16)	27.16 (± 23.937)	22.92 (± 17.902)		
Fatigue: Cycle 17 (n=22,15)	28.28 (± 22.15)	18.52 (± 18.144)		
Fatigue: Cycle 18 (n=17,14)	26.8 (± 22.243)	22.22 (± 17.433)		
Fatigue: Cycle 19 (n=12,14)	34.26 (± 31.944)	23.02 (± 20.191)		
Fatigue: Cycle 20 (n=11,13)	34.34 (± 26.036)	22.22 (± 18.144)		
Fatigue: Cycle 21 (n=11,12)	34.34 (± 32.377)	28.7 (± 21.429)		
Fatigue: Cycle 22 (n=11,11)	31.31 (± 28.029)	30.3 (± 27.707)		
Fatigue: Cycle 23 (n=11,10)	39.39 (± 28.702)	28.89 (± 25.229)		
Fatigue: Cycle 24 (n=10,10)	36.67 (± 32.309)	28.89 (± 26.294)		

Fatigue: Cycle 25 (n=10,8)	40 (± 30.18)	27.78 (± 21.414)		
Fatigue: Cycle 26 (n=7,7)	44.44 (± 27.962)	22.22 (± 14.344)		
Fatigue: Cycle 27 (n=6,8)	50 (± 30.429)	26.39 (± 22.954)		
Fatigue: Cycle 28 (n=7,8)	42.86 (± 28.276)	30.56 (± 26.394)		
Fatigue: Cycle 29 (n=6,7)	35.19 (± 23.744)	28.57 (± 21.138)		
Fatigue: Cycle 30 (n=5,7)	24.44 (± 18.257)	31.75 (± 27.539)		
Fatigue: Cycle 31 (n=3,7)	22.22 (± 29.397)	31.75 (± 29.696)		
Fatigue: Cycle 32 (n=3,6)	18.52 (± 23.13)	35.19 (± 12.989)		
Fatigue: Cycle 33 (n=3,6)	22.22 (± 29.397)	40.74 (± 20.688)		
Fatigue: Cycle 34 (n=3,6)	37.04 (± 35.717)	40.74 (± 16.728)		
Fatigue: Cycle 35 (n=2,6)	33.33 (± 47.14)	35.19 (± 16.355)		
Fatigue: Cycle 36 (n=1,5)	0 (± 99999)	40 (± 14.907)		
Fatigue: Cycle 37 (n=1,4)	0 (± 99999)	36.11 (± 21.033)		
Fatigue: Cycle 38 (n=0,4)	99999 (± 99999)	44.44 (± 27.217)		
Fatigue: Cycle 39 (n=1,3)	0 (± 99999)	51.85 (± 33.945)		
Fatigue: Cycle 40 (n=1,3)	0 (± 99999)	59.26 (± 33.945)		
Fatigue: Cycle 41 (n=0,3)	99999 (± 99999)	48.15 (± 23.13)		
Fatigue: Cycle 42 (n=0,2)	99999 (± 99999)	44.44 (± 31.427)		
Fatigue: Cycle 43 (n=0,1)	99999 (± 99999)	22.22 (± 99999)		
Fatigue: EOT (n=33,30)	33 (± 23.812)	40.56 (± 28.632)		
Nausea and Vomiting: Cycle 1 (n=61,44)	6.56 (± 13.01)	7.95 (± 17.42)		
Nausea and Vomiting: Cycle 2 (n=57,42)	7.31 (± 12.206)	7.14 (± 9.123)		
Nausea and Vomiting: Cycle 3 (n=55,40)	7.27 (± 12.735)	12.08 (± 19.967)		
Nausea and Vomiting: Cycle 4 (n=50,38)	8 (± 13.569)	4.39 (± 9.238)		
Nausea and Vomiting: Cycle 5 (n=47,34)	6.38 (± 12.794)	8.33 (± 14.935)		
Nausea and Vomiting: Cycle 6 (n=43,31)	6.98 (± 12.189)	6.99 (± 11.2)		
Nausea and Vomiting: Cycle 7 (n=39,29)	6.41 (± 12.458)	6.9 (± 15.117)		
Nausea and Vomiting: Cycle 8 (n=37,25)	7.66 (± 15.513)	3.33 (± 6.804)		
Nausea and Vomiting: Cycle 9 (n=35,26)	9.05 (± 14.766)	4.49 (± 10.064)		
Nausea and Vomiting: Cycle 10 (n=35,23)	5.71 (± 12.088)	4.35 (± 9.014)		
Nausea and Vomiting: Cycle 11 (n=35,24)	4.76 (± 10.362)	4.86 (± 9.167)		

Nausea and Vomiting: Cycle 12 (n=35,22)	4.76 (± 11.835)	6.06 (± 8.206)		
Nausea and Vomiting: Cycle 13 (n=34,21)	3.43 (± 8.97)	2.38 (± 5.976)		
Nausea and Vomiting: Cycle 14 (n=31,19)	5.38 (± 9.988)	6.14 (± 12.681)		
Nausea and Vomiting: Cycle 15 (n=30,17)	7.22 (± 12.132)	5.88 (± 16.605)		
Nausea and Vomiting: Cycle 16 (n=27,16)	4.32 (± 9.906)	3.13 (± 9.065)		
Nausea and Vomiting: Cycle 17 (n=22,15)	3.03 (± 8.351)	4.44 (± 9.894)		
Nausea and Vomiting: Cycle 18 (n=17,14)	4.9 (± 11.433)	1.19 (± 4.454)		
Nausea and Vomiting: Cycle 19 (n=12,14)	4.17 (± 10.36)	4.76 (± 12.105)		
Nausea and Vomiting: Cycle 20 (n=11,13)	6.06 (± 15.407)	1.28 (± 4.623)		
Nausea and Vomiting: Cycle 21 (n=11,12)	4.55 (± 15.076)	6.94 (± 19.408)		
Nausea and Vomiting: Cycle 22 (n=11,11)	4.55 (± 15.076)	9.09 (± 30.151)		
Nausea and Vomiting: Cycle 23 (n=11,10)	6.06 (± 15.407)	0 (± 0)		
Nausea and Vomiting: Cycle 24 (n=10,10)	6.67 (± 11.653)	3.33 (± 7.027)		
Nausea and Vomiting: Cycle 25 (n=10,8)	8.33 (± 14.164)	0 (± 0)		
Nausea and Vomiting: Cycle 26 (n=7,7)	7.14 (± 8.909)	0 (± 0)		
Nausea and Vomiting: Cycle 27 (n=6,8)	11.11 (± 20.184)	4.17 (± 11.785)		
Nausea and Vomiting: Cycle 28 (n=7,8)	9.52 (± 18.898)	2.08 (± 5.893)		
Nausea and Vomiting: Cycle 29 (n=6,7)	2.78 (± 6.804)	0 (± 0)		
Nausea and Vomiting: Cycle 30 (n=5,7)	0 (± 0)	2.38 (± 6.299)		
Nausea and Vomiting: Cycle 31 (n=3,7)	0 (± 0)	0 (± 0)		
Nausea and Vomiting: Cycle 32 (n=3,6)	5.56 (± 9.623)	0 (± 0)		
Nausea and Vomiting: Cycle 33 (n=3,6)	22.22 (± 38.49)	2.78 (± 6.804)		
Nausea and Vomiting: Cycle 34 (n=3,6)	22.22 (± 38.49)	8.33 (± 13.944)		
Nausea and Vomiting: Cycle 35 (n=2,6)	16.67 (± 23.57)	0 (± 0)		
Nausea and Vomiting: Cycle 36 (n=1,5)	0 (± 99999)	0 (± 0)		
Nausea and Vomiting: Cycle 37 (n=1,4)	0 (± 99999)	4.17 (± 8.333)		
Nausea and Vomiting: Cycle 38 (n=0,4)	99999 (± 99999)	0 (± 0)		
Nausea and Vomiting: Cycle 39 (n=1,3)	0 (± 99999)	0 (± 0)		
Nausea and Vomiting: Cycle 40 (n=1,3)	0 (± 99999)	11.11 (± 19.245)		
Nausea and Vomiting: Cycle 41 (n=0,3)	99999 (± 99999)	0 (± 0)		
Nausea and Vomiting: Cycle 42 (n=0,2)	99999 (± 99999)	0 (± 0)		
Nausea and Vomiting: Cycle 43 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Nausea and Vomiting: EOT (n=33,30)	16.16 (± 21.844)	12.78 (± 20.846)		
Pain: Cycle 1 (n=61,44)	16.39 (± 20.067)	18.18 (± 18.958)		

Pain: Cycle 2 (n=57,42)	16.67 (± 18.094)	19.05 (± 20.353)		
Pain: Cycle 3 (n=55,40)	15.76 (± 18.542)	22.5 (± 27.099)		
Pain: Cycle 4 (n=50,38)	14 (± 15.922)	23.25 (± 24.056)		
Pain: Cycle 5 (n=47,34)	15.96 (± 16.651)	18.14 (± 22.235)		
Pain: Cycle 6 (n=43,31)	15.89 (± 17.041)	20.43 (± 26.073)		
Pain: Cycle 7 (n=39,29)	20.09 (± 21.69)	22.99 (± 22.893)		
Pain: Cycle 8 (n=37,25)	17.57 (± 17.099)	14.67 (± 16.887)		
Pain: Cycle 9 (n=35,26)	20.48 (± 19.838)	19.87 (± 19.447)		
Pain: Cycle 10 (n=35,23)	19.52 (± 22.682)	18.84 (± 22.079)		
Pain: Cycle 11 (n=35,24)	19.05 (± 19.446)	13.89 (± 18.169)		
Pain: Cycle 12 (n=35,22)	20.48 (± 22.172)	16.67 (± 17.817)		
Pain: Cycle 13 (n=34,21)	17.16 (± 15.616)	15.87 (± 20.053)		
Pain: Cycle 14 (n=31,19)	14.52 (± 17.074)	21.05 (± 19.909)		
Pain: Cycle 15 (n=30,17)	15 (± 23.305)	21.57 (± 24.127)		
Pain: Cycle 16 (n=27,16)	17.28 (± 21.917)	15.63 (± 14.232)		
Pain: Cycle 17 (n=22,15)	18.94 (± 23.171)	15.56 (± 17.213)		
Pain: Cycle 18 (n=17,14)	16.67 (± 22.048)	10.71 (± 16.803)		
Pain: Cycle 19 (n=12,14)	26.39 (± 27.941)	13.1 (± 16.249)		
Pain: Cycle 20 (n=11,13)	25.76 (± 27.247)	12.82 (± 15.447)		
Pain: Cycle 21 (n=11,12)	25.76 (± 29.215)	16.67 (± 21.32)		
Pain: Cycle 22 (n=11,11)	18.18 (± 26.304)	21.21 (± 21.201)		
Pain: Cycle 23 (n=11,10)	21.21 (± 27.979)	15 (± 22.839)		
Pain: Cycle 24 (n=10,10)	28.33 (± 26.117)	20 (± 24.595)		
Pain: Cycle 25 (n=10,8)	26.67 (± 30.631)	16.67 (± 19.92)		
Pain: Cycle 26 (n=7,7)	38.1 (± 40.5)	16.67 (± 19.245)		
Pain: Cycle 27 (n=6,8)	47.22 (± 35.616)	20.83 (± 21.362)		
Pain: Cycle 28 (n=7,8)	35.71 (± 33.923)	22.92 (± 25.099)		
Pain: Cycle 29 (n=6,7)	19.44 (± 19.484)	23.81 (± 26.972)		
Pain: Cycle 30 (n=5,7)	20 (± 21.731)	19.05 (± 24.398)		
Pain: Cycle 31 (n=3,7)	16.67 (± 28.868)	26.19 (± 23.288)		
Pain: Cycle 32 (n=3,6)	16.67 (± 28.868)	27.78 (± 31.032)		

Pain: Cycle 33 (n=3,6)	16.67 (± 28.868)	25 (± 25.276)		
Pain: Cycle 34 (n=3,6)	22.22 (± 38.49)	27.78 (± 25.092)		
Pain: Cycle 35 (n=2,6)	25 (± 35.355)	22.22 (± 13.608)		
Pain: Cycle 36 (n=1,5)	0 (± 99999)	20 (± 13.944)		
Pain: Cycle 37 (n=1,4)	16.67 (± 99999)	29.17 (± 28.464)		
Pain: Cycle 38 (n=0,4)	99999 (± 99999)	29.17 (± 28.464)		
Pain: Cycle 39 (n=1,3)	0 (± 99999)	38.89 (± 25.459)		
Pain: Cycle 40 (n=1,3)	0 (± 99999)	44.44 (± 19.245)		
Pain: Cycle 41 (n=0,3)	99999 (± 99999)	55.56 (± 41.944)		
Pain: Cycle 42 (n=0,2)	99999 (± 99999)	33.33 (± 47.14)		
Pain: Cycle 43 (n=0,1)	99999 (± 99999)	33.33 (± 99999)		
Pain: EOT (n=33,30)	23.74 (± 25.695)	33.89 (± 32.009)		
Dyspnoea: Cycle 1 (n=60,44)	5 (± 12.003)	7.58 (± 15.854)		
Dyspnoea: Cycle 2 (n=57,42)	7.02 (± 15.088)	8.73 (± 18.123)		
Dyspnoea: Cycle 3 (n=55,40)	6.06 (± 12.975)	9.17 (± 21.334)		
Dyspnoea: Cycle 4 (n=50,38)	6 (± 12.936)	13.16 (± 21.28)		
Dyspnoea: Cycle 5 (n=47,34)	5.67 (± 14.445)	10.78 (± 22.801)		
Dyspnoea: Cycle 6 (n=43,31)	6.98 (± 15.53)	10.75 (± 24.925)		
Dyspnoea: Cycle 7 (n=39,29)	11.11 (± 22.076)	10.34 (± 20.125)		
Dyspnoea: Cycle 8 (n=37,25)	15.32 (± 21.652)	6.67 (± 13.608)		
Dyspnoea: Cycle 9 (n=35,26)	9.52 (± 20.725)	5.13 (± 12.265)		
Dyspnoea: Cycle 10 (n=35,23)	9.52 (± 15.278)	10.14 (± 21.165)		
Dyspnoea: Cycle 11 (n=35,24)	5.71 (± 12.746)	9.72 (± 15.477)		
Dyspnoea: Cycle 12 (n=35,22)	8.57 (± 14.781)	6.06 (± 13.159)		
Dyspnoea: Cycle 13 (n=34,21)	10.78 (± 15.829)	12.7 (± 19.653)		
Dyspnoea: Cycle 14 (n=31,19)	9.68 (± 15.38)	8.77 (± 15.08)		
Dyspnoea: Cycle 15 (n=30,17)	8.89 (± 14.993)	9.8 (± 15.656)		
Dyspnoea: Cycle 16 (n=27,16)	6.17 (± 13.195)	6.25 (± 13.437)		
Dyspnoea: Cycle 17 (n=22,15)	10.61 (± 15.891)	6.67 (± 13.801)		
Dyspnoea: Cycle 18 (n=17,14)	7.84 (± 14.575)	4.76 (± 12.105)		
Dyspnoea: Cycle 19 (n=12,14)	13.89 (± 17.164)	4.76 (± 12.105)		
Dyspnoea: Cycle 20 (n=11,13)	6.06 (± 13.484)	5.13 (± 12.518)		

Dyspnoea: Cycle 21 (n=11,12)	12.12 (± 16.817)	8.33 (± 15.076)		
Dyspnoea: Cycle 22 (n=11,11)	9.09 (± 15.57)	9.09 (± 15.57)		
Dyspnoea: Cycle 23 (n=11,10)	6.06 (± 13.484)	13.33 (± 17.213)		
Dyspnoea: Cycle 24 (n=10,10)	6.67 (± 14.055)	13.33 (± 17.213)		
Dyspnoea: Cycle 25 (n=10,8)	13.33 (± 23.307)	8.33 (± 15.43)		
Dyspnoea: Cycle 26 (n=7,7)	9.52 (± 16.265)	9.52 (± 16.265)		
Dyspnoea: Cycle 27 (n=6,8)	11.11 (± 27.217)	8.33 (± 15.43)		
Dyspnoea: Cycle 28 (n=7,8)	19.05 (± 17.817)	12.5 (± 17.252)		
Dyspnoea: Cycle 29 (n=6,7)	11.11 (± 27.217)	19.05 (± 17.817)		
Dyspnoea: Cycle 30 (n=5,7)	6.67 (± 14.907)	14.29 (± 17.817)		
Dyspnoea: Cycle 31 (n=3,7)	0 (± 0)	9.52 (± 16.265)		
Dyspnoea: Cycle 32 (n=3,6)	11.11 (± 19.245)	16.67 (± 27.889)		
Dyspnoea: Cycle 33 (n=3,6)	22.22 (± 38.49)	11.11 (± 17.213)		
Dyspnoea: Cycle 34 (n=3,6)	11.11 (± 19.245)	16.67 (± 27.889)		
Dyspnoea: Cycle 35 (n=2,6)	16.67 (± 23.57)	11.11 (± 17.213)		
Dyspnoea: Cycle 36 (n=1,5)	0 (± 99999)	26.67 (± 27.889)		
Dyspnoea: Cycle 37 (n=1,4)	0 (± 99999)	8.33 (± 16.667)		
Dyspnoea: Cycle 38 (n=0,4)	99999 (± 99999)	8.33 (± 16.667)		
Dyspnoea: Cycle 39 (n=1,3)	0 (± 99999)	0 (± 0)		
Dyspnoea: Cycle 40 (n=1,3)	0 (± 99999)	0 (± 0)		
Dyspnoea: Cycle 41 (n=0,3)	99999 (± 99999)	0 (± 0)		
Dyspnoea: Cycle 42 (n=0,2)	99999 (± 99999)	16.67 (± 23.57)		
Dyspnoea: Cycle 43 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Dyspnoea: EOT (n=33,30)	14.14 (± 16.73)	13.33 (± 24.132)		
Insomnia: Cycle 1 (n=61,44)	13.11 (± 20.438)	25.76 (± 27.715)		
Insomnia: Cycle 2 (n=57,42)	9.36 (± 16.372)	19.84 (± 23.35)		
Insomnia: Cycle 3 (n=55,40)	12.12 (± 17.408)	26.67 (± 26.366)		
Insomnia: Cycle 4 (n=50,38)	11.33 (± 19.76)	24.56 (± 27.601)		
Insomnia: Cycle 5 (n=47,34)	9.22 (± 19.289)	17.65 (± 26.253)		
Insomnia: Cycle 6 (n=43,31)	10.85 (± 18.857)	20.43 (± 26.774)		
Insomnia: Cycle 7 (n=39,29)	9.4 (± 18.651)	21.84 (± 28.558)		
Insomnia: Cycle 8 (n=37,25)	10.81 (± 20.867)	21.33 (± 21.257)		

Insomnia: Cycle 9 (n=35,26)	11.43 (± 19.708)	20.51 (± 23.242)		
Insomnia: Cycle 10 (n=35,23)	12.38 (± 18.232)	21.74 (± 21.576)		
Insomnia: Cycle 11 (n=35,24)	12.38 (± 18.232)	22.22 (± 27.217)		
Insomnia: Cycle 12 (n=35,22)	6.67 (± 15.76)	22.73 (± 27.958)		
Insomnia: Cycle 13 (n=34,21)	9.8 (± 15.417)	23.81 (± 21.455)		
Insomnia: Cycle 14 (n=31,19)	8.6 (± 17.144)	22.81 (± 19.413)		
Insomnia: Cycle 15 (n=29,17)	9.2 (± 17.586)	25.49 (± 25.082)		
Insomnia: Cycle 16 (n=27,16)	9.88 (± 20.286)	25 (± 28.545)		
Insomnia: Cycle 17 (n=22,15)	6.06 (± 16.703)	22.22 (± 24.125)		
Insomnia: Cycle 18 (n=17,14)	11.76 (± 16.42)	23.81 (± 24.209)		
Insomnia: Cycle 19 (n=12,14)	13.89 (± 22.285)	23.81 (± 24.209)		
Insomnia: Cycle 20 (n=11,13)	9.09 (± 15.57)	25.64 (± 24.167)		
Insomnia: Cycle 21 (n=11,12)	18.18 (± 22.918)	30.56 (± 26.432)		
Insomnia: Cycle 22 (n=11,11)	15.15 (± 22.918)	30.3 (± 27.707)		
Insomnia: Cycle 23 (n=11,10)	15.15 (± 17.408)	30 (± 33.148)		
Insomnia: Cycle 24 (n=10,10)	10 (± 22.498)	33.33 (± 27.217)		
Insomnia: Cycle 25 (n=10,8)	23.33 (± 27.442)	29.17 (± 27.817)		
Insomnia: Cycle 26 (n=7,7)	9.52 (± 16.265)	23.81 (± 25.198)		
Insomnia: Cycle 27 (n=6,8)	27.78 (± 38.968)	33.33 (± 25.198)		
Insomnia: Cycle 28 (n=7,8)	23.81 (± 25.198)	25 (± 29.547)		
Insomnia: Cycle 29 (n=6,7)	22.22 (± 27.217)	38.1 (± 35.635)		
Insomnia: Cycle 30 (n=5,7)	6.67 (± 14.907)	28.57 (± 29.991)		
Insomnia: Cycle 31 (n=3,7)	11.11 (± 19.245)	19.05 (± 26.227)		
Insomnia: Cycle 32 (n=3,6)	22.22 (± 19.245)	27.78 (± 25.092)		
Insomnia: Cycle 33 (n=3,6)	22.22 (± 19.245)	22.22 (± 27.217)		
Insomnia: Cycle 34 (n=3,6)	22.22 (± 38.49)	27.78 (± 25.092)		
Insomnia: Cycle 35 (n=2,6)	16.67 (± 23.57)	27.78 (± 25.092)		
Insomnia: Cycle 36 (n=1,5)	0 (± 99999)	26.67 (± 27.889)		
Insomnia: Cycle 37 (n=1,4)	0 (± 99999)	16.67 (± 19.245)		
Insomnia: Cycle 38 (n=0,4)	99999 (± 99999)	33.33 (± 27.217)		
Insomnia: Cycle 39 (n=1,3)	0 (± 99999)	22.22 (± 19.245)		

Insomnia: Cycle 40 (n=1,3)	0 (± 99999)	33.33 (± 0)		
Insomnia: Cycle 41 (n=0,3)	99999 (± 99999)	22.22 (± 19.245)		
Insomnia: Cycle 42 (n=0,2)	99999 (± 99999)	16.67 (± 23.57)		
Insomnia: Cycle 43 (n=0,1)	99999 (± 99999)	33.33 (± 99999)		
Insomnia: EOT (n=33,30)	16.16 (± 26.512)	25.56 (± 33.543)		
Appetite Loss: Cycle 1 (n=61,44)	12.57 (± 21.225)	15.91 (± 23.282)		
Appetite Loss: Cycle 2 (n=57,42)	16.96 (± 21.009)	18.25 (± 22.333)		
Appetite Loss: Cycle 3 (n=55,40)	13.94 (± 18.912)	20.83 (± 28.929)		
Appetite Loss: Cycle 4 (n=50,38)	14 (± 24.365)	16.67 (± 26.565)		
Appetite Loss: Cycle 5 (n=47,34)	10.64 (± 20.974)	15.69 (± 28.704)		
Appetite Loss: Cycle 6 (n=43,31)	10.85 (± 20.212)	18.28 (± 30.839)		
Appetite Loss: Cycle 7 (n=39,29)	14.53 (± 22.679)	14.94 (± 28.986)		
Appetite Loss: Cycle 8 (n=37,25)	16.22 (± 25.606)	14.67 (± 25.604)		
Appetite Loss: Cycle 9 (n=35,26)	14.29 (± 18.587)	14.1 (± 26.954)		
Appetite Loss: Cycle 10 (n=35,23)	13.33 (± 21.693)	17.39 (± 28.194)		
Appetite Loss: Cycle 11 (n=35,24)	15.24 (± 21.907)	8.33 (± 22.522)		
Appetite Loss: Cycle 12 (n=35,22)	13.33 (± 25.82)	12.12 (± 24.224)		
Appetite Loss: Cycle 13 (n=34,21)	13.73 (± 21.893)	7.94 (± 14.548)		
Appetite Loss: Cycle 14 (n=31,19)	10.75 (± 21.751)	10.53 (± 19.413)		
Appetite Loss: Cycle 15 (n=30,17)	13.33 (± 24.132)	15.69 (± 29.149)		
Appetite Loss: Cycle 16 (n=27,16)	13.58 (± 23.13)	8.33 (± 19.245)		
Appetite Loss: Cycle 17 (n=22,15)	10.61 (± 23.874)	6.67 (± 18.687)		
Appetite Loss: Cycle 18 (n=17,14)	17.65 (± 29.149)	9.52 (± 20.375)		
Appetite Loss: Cycle 19 (n=12,14)	19.44 (± 33.207)	9.52 (± 27.514)		
Appetite Loss: Cycle 20 (n=11,13)	21.21 (± 34.23)	5.13 (± 12.518)		
Appetite Loss: Cycle 21 (n=11,12)	21.21 (± 34.23)	16.67 (± 22.473)		
Appetite Loss: Cycle 22 (n=11,11)	18.18 (± 31.14)	15.15 (± 22.918)		
Appetite Loss: Cycle 23 (n=11,10)	18.18 (± 31.14)	10 (± 22.498)		
Appetite Loss: Cycle 24 (n=10,10)	23.33 (± 35.312)	13.33 (± 23.307)		
Appetite Loss: Cycle 25 (n=10,8)	23.33 (± 41.722)	8.33 (± 23.57)		
Appetite Loss: Cycle 26 (n=7,7)	38.1 (± 48.795)	4.76 (± 12.599)		

Appetite Loss: Cycle 27 (n=6,8)	33.33 (± 42.164)	12.5 (± 35.355)		
Appetite Loss: Cycle 28 (n=7,8)	28.57 (± 40.5)	16.67 (± 35.635)		
Appetite Loss: Cycle 29 (n=6,7)	11.11 (± 27.217)	4.76 (± 12.599)		
Appetite Loss: Cycle 30 (n=5,7)	0 (± 0)	4.76 (± 12.599)		
Appetite Loss: Cycle 31 (n=3,7)	0 (± 0)	9.52 (± 25.198)		
Appetite Loss: Cycle 32 (n=3,6)	11.11 (± 19.245)	16.67 (± 27.889)		
Appetite Loss: Cycle 33 (n=3,6)	22.22 (± 38.49)	16.67 (± 27.889)		
Appetite Loss: Cycle 34 (n=3,6)	33.33 (± 57.735)	27.78 (± 32.773)		
Appetite Loss: Cycle 35 (n=2,6)	33.33 (± 47.14)	11.11 (± 27.217)		
Appetite Loss: Cycle 36 (n=1,5)	0 (± 99999)	0 (± 0)		
Appetite Loss: Cycle 37 (n=1,4)	0 (± 99999)	16.67 (± 19.245)		
Appetite Loss: Cycle 38 (n=0,4)	99999 (± 99999)	16.67 (± 19.245)		
Appetite Loss: Cycle 39 (n=1,3)	0 (± 99999)	11.11 (± 19.245)		
Appetite Loss: Cycle 40 (n=1,3)	0 (± 99999)	11.11 (± 19.245)		
Appetite Loss: Cycle 41 (n=0,3)	99999 (± 99999)	22.22 (± 38.49)		
Appetite Loss: Cycle 42 (n=0,2)	99999 (± 99999)	16.67 (± 23.57)		
Appetite Loss: Cycle 43 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Appetite Loss: EOT (n=33,30)	27.27 (± 34.816)	26.67 (± 32.044)		
Constipation: Cycle 1 (n=61,44)	7.1 (± 17.336)	9.09 (± 18.135)		
Constipation: Cycle 2 (n=57,42)	3.51 (± 10.321)	13.49 (± 26.605)		
Constipation: Cycle 3 (n=55,40)	7.27 (± 15.303)	4.17 (± 13.477)		
Constipation: Cycle 4 (n=50,38)	6.67 (± 15.058)	5.26 (± 12.318)		
Constipation: Cycle 5 (n=47,34)	3.55 (± 12.499)	2.94 (± 12.627)		
Constipation: Cycle 6 (n=43,31)	3.88 (± 10.812)	2.15 (± 8.324)		
Constipation: Cycle 7 (n=39,29)	3.42 (± 10.245)	5.75 (± 17.97)		
Constipation: Cycle 8 (n=37,25)	3.6 (± 13.109)	4 (± 14.657)		
Constipation: Cycle 9 (n=35,26)	6.67 (± 15.76)	3.85 (± 14.382)		
Constipation: Cycle 10 (n=35,23)	2.86 (± 9.468)	5.8 (± 16.368)		
Constipation: Cycle 11 (n=35,24)	3.81 (± 13.459)	2.78 (± 9.411)		
Constipation: Cycle 12 (n=35,22)	5.71 (± 12.746)	4.55 (± 11.708)		
Constipation: Cycle 13 (n=34,21)	2.94 (± 9.597)	1.59 (± 7.274)		
Constipation: Cycle 14 (n=31,19)	1.08 (± 5.987)	3.51 (± 10.51)		
Constipation: Cycle 15 (n=30,17)	2.22 (± 8.457)	3.92 (± 16.169)		

Constipation: Cycle 16 (n=27,16)	2.47 (± 8.896)	6.25 (± 13.437)		
Constipation: Cycle 17 (n=22,15)	6.06 (± 13.159)	2.22 (± 8.607)		
Constipation: Cycle 18 (n=17,14)	3.92 (± 11.07)	4.76 (± 12.105)		
Constipation: Cycle 19 (n=12,14)	0 (± 0)	9.52 (± 20.375)		
Constipation: Cycle 20 (n=11,13)	0 (± 0)	0 (± 0)		
Constipation: Cycle 21 (n=11,12)	0 (± 0)	2.78 (± 9.623)		
Constipation: Cycle 22 (n=11,11)	0 (± 0)	12.12 (± 30.814)		
Constipation: Cycle 23 (n=11,10)	0 (± 0)	3.33 (± 10.541)		
Constipation: Cycle 24 (n=10,10)	0 (± 0)	6.67 (± 14.055)		
Constipation: Cycle 25 (n=10,8)	3.33 (± 10.541)	0 (± 0)		
Constipation: Cycle 26 (n=7,7)	0 (± 0)	4.76 (± 12.599)		
Constipation: Cycle 27 (n=6,8)	5.56 (± 13.608)	4.17 (± 11.785)		
Constipation: Cycle 28 (n=7,8)	4.76 (± 12.599)	4.17 (± 11.785)		
Constipation: Cycle 29 (n=5,7)	0 (± 0)	4.76 (± 12.599)		
Constipation: Cycle 30 (n=4,7)	0 (± 0)	4.76 (± 12.599)		
Constipation: Cycle 31 (n=2,7)	0 (± 0)	4.76 (± 12.599)		
Constipation: Cycle 32 (n=3,6)	0 (± 0)	0 (± 0)		
Constipation: Cycle 33 (n=3,6)	0 (± 0)	5.56 (± 13.608)		
Constipation: Cycle 34 (n=3,6)	0 (± 0)	5.56 (± 13.608)		
Constipation: Cycle 35 (n=2,6)	0 (± 0)	5.56 (± 13.608)		
Constipation: Cycle 36 (n=1,5)	0 (± 99999)	13.33 (± 29.814)		
Constipation: Cycle 37 (n=1,4)	0 (± 99999)	0 (± 0)		
Constipation: Cycle 38 (n=0,4)	99999 (± 99999)	0 (± 0)		
Constipation: Cycle 39 (n=1,3)	0 (± 99999)	11.11 (± 19.245)		
Constipation: Cycle 40 (n=1,3)	0 (± 99999)	0 (± 0)		
Constipation: Cycle 41 (n=0,3)	99999 (± 99999)	0 (± 0)		
Constipation: Cycle 42 (n=0,2)	99999 (± 99999)	0 (± 0)		
Constipation: Cycle 43 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Constipation: EOT (n=33,30)	10.1 (± 19.516)	3.33 (± 10.171)		
Diarrhoea: Cycle 1 (n=61,43)	14.21 (± 22.327)	11.63 (± 17.644)		
Diarrhoea: Cycle 2 (n=57,41)	18.13 (± 26.027)	17.07 (± 25.951)		
Diarrhoea: Cycle 3 (n=55,40)	16.36 (± 24.74)	24.17 (± 25.021)		
Diarrhoea: Cycle 4 (n=50,38)	22 (± 27.446)	15.79 (± 21.556)		

Diarrhoea: Cycle 5 (n=47,34)	22.7 (± 26.105)	21.57 (± 23.039)		
Diarrhoea: Cycle 6 (n=43,31)	24.03 (± 29.39)	22.58 (± 21.751)		
Diarrhoea: Cycle 7 (n=39,29)	29.06 (± 27.762)	25.29 (± 29.08)		
Diarrhoea: Cycle 8 (n=37,25)	26.13 (± 27.369)	20 (± 28.868)		
Diarrhoea: Cycle 9 (n=35,26)	30.48 (± 30.648)	29.49 (± 33.102)		
Diarrhoea: Cycle 10 (n=35,23)	24.76 (± 26)	27.54 (± 29.563)		
Diarrhoea: Cycle 11 (n=35,24)	23.81 (± 25.012)	23.61 (± 23.008)		
Diarrhoea: Cycle 12 (n=35,22)	21.9 (± 22.785)	18.18 (± 22.366)		
Diarrhoea: Cycle 13 (n=34,21)	21.57 (± 21.528)	19.05 (± 27.021)		
Diarrhoea: Cycle 14 (n=31,19)	23.66 (± 23.084)	19.3 (± 20.233)		
Diarrhoea: Cycle 15 (n=30,17)	21.11 (± 23.947)	25.49 (± 22.14)		
Diarrhoea: Cycle 16 (n=27,16)	18.52 (± 25.036)	20.83 (± 20.638)		
Diarrhoea: Cycle 17 (n=22,15)	21.21 (± 19.37)	15.56 (± 24.774)		
Diarrhoea: Cycle 18 (n=17,14)	25.49 (± 27.712)	19.05 (± 25.198)		
Diarrhoea: Cycle 19 (n=12,14)	13.89 (± 17.164)	19.05 (± 21.54)		
Diarrhoea: Cycle 20 (n=11,13)	27.27 (± 20.101)	23.08 (± 25.036)		
Diarrhoea: Cycle 21 (n=11,12)	33.33 (± 29.814)	25 (± 28.868)		
Diarrhoea: Cycle 22 (n=11,11)	18.18 (± 31.14)	21.21 (± 26.968)		
Diarrhoea: Cycle 23 (n=11,10)	24.24 (± 33.635)	26.67 (± 30.631)		
Diarrhoea: Cycle 24 (n=10,10)	23.33 (± 22.498)	23.33 (± 31.623)		
Diarrhoea: Cycle 25 (n=10,8)	16.67 (± 17.568)	29.17 (± 27.817)		
Diarrhoea: Cycle 26 (n=7,7)	19.05 (± 26.227)	28.57 (± 29.991)		
Diarrhoea: Cycle 27 (n=6,8)	22.22 (± 17.213)	37.5 (± 33.034)		
Diarrhoea: Cycle 28 (n=7,8)	14.29 (± 17.817)	29.17 (± 27.817)		
Diarrhoea: Cycle 29 (n=5,7)	0 (± 0)	28.57 (± 29.991)		
Diarrhoea: Cycle 30 (n=4,7)	0 (± 0)	38.1 (± 23.002)		
Diarrhoea: Cycle 31 (n=2,7)	0 (± 0)	33.33 (± 27.217)		
Diarrhoea: Cycle 32 (n=3,6)	22.22 (± 19.245)	50 (± 27.889)		
Diarrhoea: Cycle 33 (n=3,6)	11.11 (± 19.245)	50 (± 27.889)		
Diarrhoea: Cycle 34 (n=3,6)	33.33 (± 33.333)	44.44 (± 27.217)		
Diarrhoea: Cycle 35 (n=2,6)	16.67 (± 23.57)	38.89 (± 32.773)		

Diarrhoea: Cycle 36 (n=1,5)	0 (± 99999)	40 (± 43.461)		
Diarrhoea: Cycle 37 (n=1,4)	0 (± 99999)	25 (± 31.914)		
Diarrhoea: Cycle 38 (n=0,4)	99999 (± 99999)	41.67 (± 31.914)		
Diarrhoea: Cycle 39 (n=1,3)	0 (± 99999)	33.33 (± 33.333)		
Diarrhoea: Cycle 40 (n=1,3)	0 (± 99999)	44.44 (± 38.49)		
Diarrhoea: Cycle 41 (n=0,3)	99999 (± 99999)	44.44 (± 38.49)		
Diarrhoea: Cycle 42 (n=0,2)	99999 (± 99999)	50 (± 23.57)		
Diarrhoea: Cycle 43 (n=0,1)	99999 (± 99999)	66.67 (± 99999)		
Diarrhoea: EOT (n=33,30)	24.24 (± 29.194)	17.78 (± 24.343)		
Financial Difficulties: Cycle 1 (n=61,43)	25.68 (± 35.691)	31.01 (± 33.646)		
Financial Difficulties: Cycle 2 (n=57,41)	23.39 (± 28.843)	21.95 (± 26.468)		
Financial Difficulties: Cycle 3 (n=55,40)	23.03 (± 30.002)	30 (± 34.427)		
Financial Difficulties: Cycle 4 (n=50,38)	24 (± 30.147)	28.95 (± 27.037)		
Financial Difficulties: Cycle 5 (n=47,34)	26.24 (± 34.005)	25.49 (± 29.654)		
Financial Difficulties: Cycle 6 (n=43,31)	27.13 (± 35.078)	26.88 (± 31.528)		
Financial Difficulties: Cycle 7 (n=39,29)	29.06 (± 31.696)	27.59 (± 32.206)		
Financial Difficulties: Cycle 8 (n=37,25)	30.63 (± 32.753)	25.33 (± 29.313)		
Financial Difficulties: Cycle 9 (n=35,26)	22.86 (± 28.892)	20.51 (± 29.929)		
Financial Difficulties: Cycle 10 (n=35,23)	25.71 (± 28.105)	24.64 (± 30.513)		
Financial Difficulties: Cycle 11 (n=35,24)	26.67 (± 27.771)	23.61 (± 28.622)		
Financial Difficulties: Cycle 12 (n=35,22)	26.67 (± 30.033)	19.7 (± 26.546)		
Financial Difficulties: Cycle 13 (n=34,21)	23.53 (± 27.864)	19.05 (± 30.861)		
Financial Difficulties: Cycle 14 (n=31,19)	23.66 (± 28.795)	17.54 (± 28.04)		
Financial Difficulties: Cycle 15 (n=30,17)	21.11 (± 22.289)	19.61 (± 29.009)		
Financial Difficulties: Cycle 16 (n=27,16)	22.22 (± 22.646)	18.75 (± 29.736)		
Financial Difficulties: Cycle 17 (n=22,15)	19.7 (± 24.471)	15.56 (± 27.794)		
Financial Difficulties: Cycle 18 (n=17,14)	17.65 (± 29.149)	16.67 (± 21.681)		
Financial Difficulties: Cycle 19 (n=12,14)	22.22 (± 32.824)	14.29 (± 17.118)		
Financial Difficulties: Cycle 20 (n=11,13)	15.15 (± 22.918)	15.38 (± 29.235)		
Financial Difficulties: Cycle 21 (n=11,12)	24.24 (± 33.635)	16.67 (± 30.151)		
Financial Difficulties: Cycle 22 (n=11,11)	18.18 (± 27.34)	15.15 (± 22.918)		
Financial Difficulties: Cycle 23 (n=11,10)	15.15 (± 22.918)	20 (± 32.203)		

Financial Difficulties: Cycle 24 (n=10, 10)	20 (± 28.109)	16.67 (± 32.394)		
Financial Difficulties: Cycle 25 (n=10, 8)	16.67 (± 28.328)	29.17 (± 37.533)		
Financial Difficulties: Cycle 26 (n=7, 7)	23.81 (± 31.706)	28.57 (± 40.5)		
Financial Difficulties: Cycle 27 (n=6, 8)	16.67 (± 27.889)	20.83 (± 35.355)		
Financial Difficulties: Cycle 28 (n=7, 8)	19.05 (± 26.227)	20.83 (± 35.355)		
Financial Difficulties: Cycle 29 (n=5, 7)	13.33 (± 29.814)	19.05 (± 37.796)		
Financial Difficulties: Cycle 30 (n=4, 7)	16.67 (± 33.333)	19.05 (± 37.796)		
Financial Difficulties: Cycle 31 (n=2, 7)	33.33 (± 47.14)	19.05 (± 37.796)		
Financial Difficulties: Cycle 32 (n=3, 6)	22.22 (± 38.49)	22.22 (± 40.369)		
Financial Difficulties: Cycle 33 (n=3, 6)	33.33 (± 33.333)	22.22 (± 40.369)		
Financial Difficulties: Cycle 34 (n=3, 6)	22.22 (± 19.245)	22.22 (± 40.369)		
Financial Difficulties: Cycle 35 (n=2, 6)	50 (± 23.57)	22.22 (± 40.369)		
Financial Difficulties: Cycle 36 (n=1, 5)	0 (± 99999)	20 (± 44.721)		
Financial Difficulties: Cycle 37 (n=1, 4)	33.33 (± 99999)	8.33 (± 16.667)		
Financial Difficulties: Cycle 38 (n=0, 4)A	99999 (± 99999)	8.33 (± 16.667)		
Financial Difficulties: Cycle 39 (n=1, 3)	0 (± 99999)	11.11 (± 19.245)		
Financial Difficulties: Cycle 40 (n=1, 3)	33.33 (± 99999)	11.11 (± 19.245)		
Financial Difficulties: Cycle 41 (n=0, 3)	99999 (± 99999)	22.22 (± 19.245)		
Financial Difficulties: Cycle 42 (n=0, 2)	99999 (± 99999)	0 (± 0)		
Financial Difficulties: Cycle 43 (n=0, 1)	99999 (± 99999)	0 (± 99999)		
Financial Difficulties: EOT (n=33, 30)	30.3 (± 29.302)	23.33 (± 26.479)		

Statistical analyses

No statistical analyses for this end point

Secondary: Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21)

End point title	Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21)
-----------------	---

End point description:

EORTC QLQ-GI-NET 21 was a 21-item questionnaire. These 21 questions assesses endocrine symptoms, gastrointestinal (G.I.) symptoms, treatment related symptoms, social functioning, disease related worries, muscle/bone pain, sexual function, information/communication function and body image. Each item was answered on a 4-point scale: 1 =not at all, 2 =a little, 3 =quite a bit, 4 =very much; where

higher scores indicated more severe symptoms/problems. Scores averaged, transformed to 0-100 scale; higher score=more severe symptoms. Here, "99999" for mean and standard deviation signifies data not available (NA) as none of the subjects were evaluable in the given group at this time point. FAS population and 'n' signifies those subjects who were evaluable at specified time point for each arm, respectively.

End point type	Secondary
End point timeframe:	
Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, End of treatment (up to maximum duration of 1226 days)	

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: units on a scale				
arithmetic mean (standard deviation)				
Endocrine Symptoms: Cycle 1 (n=61,44)	9.47 (± 14.746)	15.66 (± 20.378)		
Endocrine Symptoms: Cycle 2 (n=57,41)	9.94 (± 14.347)	14.91 (± 16.407)		
Endocrine Symptoms: Cycle 3 (n=55,40)	14.75 (± 20.066)	11.67 (± 14.443)		
Endocrine Symptoms: Cycle 4 (n=50,37)	12.67 (± 15.227)	12.31 (± 14.531)		
Endocrine Symptoms: Cycle 5 (n=47,33)	12.29 (± 13.752)	8.08 (± 12.507)		
Endocrine Symptoms: Cycle 6 (n=43,31)	13.18 (± 16.49)	9.32 (± 13.788)		
Endocrine Symptoms: Cycle 7 (n=39,29)	12.82 (± 14.315)	12.07 (± 16.538)		
Endocrine Symptoms: Cycle 8 (n=37,25)	13.81 (± 18.408)	10.67 (± 14.515)		
Endocrine Symptoms: Cycle 9 (n=35,26)	10.16 (± 14.851)	11.11 (± 14.741)		
Endocrine Symptoms: Cycle 10 (n=35,23)	10.16 (± 13.304)	14.01 (± 18.416)		
Endocrine Symptoms: Cycle 11 (n=35,24)	13.02 (± 16.934)	13.43 (± 19.653)		
Endocrine Symptoms: Cycle 12 (n=35,22)	12.06 (± 16.693)	11.62 (± 17.644)		
Endocrine Symptoms: Cycle 13 (n=34,21)	10.46 (± 14.459)	11.64 (± 15.899)		
Endocrine Symptoms: Cycle 14 (n=31,19)	12.19 (± 16.815)	14.62 (± 18.538)		
Endocrine Symptoms: Cycle 15 (n=30,17)	13.33 (± 18.082)	15.69 (± 18.864)		
Endocrine Symptoms: Cycle 16 (n=27,16)	10.7 (± 16.155)	9.03 (± 11.631)		
Endocrine Symptoms: Cycle 17 (n=22,15)	12.12 (± 18.753)	8.89 (± 10.457)		
Endocrine Symptoms: Cycle 18 (n=17,14)	11.11 (± 18.84)	11.9 (± 14.756)		
Endocrine Symptoms: Cycle 19 (n=12,14)	14.81 (± 21.364)	6.35 (± 11.293)		
Endocrine Symptoms: Cycle 20 (n=11,13)	15.15 (± 20.045)	11.11 (± 17.568)		

Endocrine Symptoms: Cycle 21 (n=11,12)	20.2 (± 20.975)	9.26 (± 12.385)		
Endocrine Symptoms: Cycle 22 (n=11,11)	14.14 (± 19.303)	16.16 (± 21.294)		
Endocrine Symptoms: Cycle 23 (n=11,10)	18.18 (± 15.131)	13.33 (± 16.397)		
Endocrine Symptoms: Cycle 24 (n=10,10)	22.22 (± 31.427)	13.33 (± 14.628)		
Endocrine Symptoms: Cycle 25 (n=10,8)	16.67 (± 23.57)	8.33 (± 12.944)		
Endocrine Symptoms: Cycle 26 (n=7,7)	22.22 (± 27.962)	7.94 (± 13.929)		
Endocrine Symptoms: Cycle 27 (n=6,8)	22.22 (± 28.109)	9.72 (± 12.511)		
Endocrine Symptoms: Cycle 28 (n=7,8)	19.05 (± 29.197)	12.5 (± 18.245)		
Endocrine Symptoms: Cycle 29 (n=6,7)	12.96 (± 12.989)	11.11 (± 12.83)		
Endocrine Symptoms: Cycle 30 (n=5,7)	8.89 (± 9.296)	14.29 (± 13.929)		
Endocrine Symptoms: Cycle 31 (n=3,7)	14.81 (± 6.415)	12.7 (± 11.878)		
Endocrine Symptoms: Cycle 32 (n=3,6)	7.41 (± 12.83)	14.81 (± 13.456)		
Endocrine Symptoms: Cycle 33 (n=3,6)	11.11 (± 0)	16.67 (± 11.653)		
Endocrine Symptoms: Cycle 34 (n=3,6)	18.52 (± 6.415)	20.37 (± 23.744)		
Endocrine Symptoms: Cycle 35 (n=2,6)	22.22 (± 0)	16.67 (± 16.851)		
Endocrine Symptoms: Cycle 36 (n=1,5)	22.22 (± 99999)	17.78 (± 18.592)		
Endocrine Symptoms: Cycle 37 (n=1,4)	22.22 (± 99999)	5.56 (± 11.111)		
Endocrine Symptoms: Cycle 38 (n=0,4)	99999 (± 99999)	8.33 (± 10.638)		
Endocrine Symptoms: Cycle 39 (n=1,3)	22.22 (± 99999)	11.11 (± 11.111)		
Endocrine Symptoms: Cycle 40 (n=1,3)	22.22 (± 99999)	11.11 (± 11.111)		
Endocrine Symptoms: Cycle 41 (n=0,3)	99999 (± 99999)	11.11 (± 11.111)		
Endocrine Symptoms: Cycle 42 (n=0,2)	99999 (± 99999)	0 (± 0)		
Endocrine Symptoms: Cycle 43 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Endocrine Symptoms: EOT (n=33,29)	13.8 (± 15.474)	11.11 (± 16.534)		
Gastrointestinal Symptoms: Cycle 1 (n=61,44)	15.41 (± 14.633)	15.3 (± 13.301)		
Gastrointestinal Symptoms: Cycle 2 (n=57,41)	17.66 (± 14.057)	17.72 (± 13.631)		
Gastrointestinal Symptoms: Cycle 3 (n=55,40)	20.24 (± 17.543)	19.5 (± 16.702)		
Gastrointestinal Symptoms: Cycle 4 (n=50,38)	19.47 (± 16.814)	19.3 (± 17.315)		
Gastrointestinal Symptoms: Cycle 5 (n=47,33)	15.18 (± 13.528)	21.01 (± 17.569)		
Gastrointestinal Symptoms: Cycle 6 (n=43,31)	18.76 (± 16.982)	21.51 (± 20.273)		
Gastrointestinal Symptoms: Cycle 7 (n=39,29)	18.63 (± 19.114)	20.23 (± 18.728)		

Gastrointestinal Symptoms: Cycle 8 (n=37,25)	20.72 (\pm 19.359)	19.47 (\pm 15.743)		
Gastrointestinal Symptoms: Cycle 9 (n=35,26)	18.86 (\pm 18.04)	19.49 (\pm 17.681)		
Gastrointestinal Symptoms: Cycle 10 (n=35,23)	18.38 (\pm 17.916)	19.78 (\pm 18.315)		
Gastrointestinal Symptoms: Cycle 11 (n=35,24)	18.86 (\pm 15.295)	16.94 (\pm 17.36)		
Gastrointestinal Symptoms: Cycle 12 (n=35,22)	18.86 (\pm 18.04)	18.79 (\pm 20.741)		
Gastrointestinal Symptoms: Cycle 13 (n=34,21)	18.04 (\pm 17.641)	14.6 (\pm 13.6)		
Gastrointestinal Symptoms: Cycle 14 (n=31,19)	18.06 (\pm 18.871)	16.49 (\pm 13.943)		
Gastrointestinal Symptoms: Cycle 15 (n=30,17)	19.56 (\pm 17.934)	22.35 (\pm 22.966)		
Gastrointestinal Symptoms: Cycle 16 (n=27,16)	17.53 (\pm 17.458)	17.5 (\pm 14.782)		
Gastrointestinal Symptoms: Cycle 17 (n=22,15)	18.18 (\pm 19.099)	13.78 (\pm 12.206)		
Gastrointestinal Symptoms: Cycle 18 (n=17,14)	24.31 (\pm 20.942)	15.71 (\pm 12.433)		
Gastrointestinal Symptoms: Cycle 19 (n=12,14)	23.89 (\pm 21.36)	20.48 (\pm 20.5)		
Gastrointestinal Symptoms: Cycle 20 (n=11,13)	25.45 (\pm 22.473)	16.41 (\pm 15.303)		
Gastrointestinal Symptoms: Cycle 21 (n=11,12)	29.09 (\pm 22.759)	17.22 (\pm 16.927)		
Gastrointestinal Symptoms: Cycle 22 (n=11,11)	23.03 (\pm 21.574)	18.18 (\pm 18.641)		
Gastrointestinal Symptoms: Cycle 23 (n=11,10)	27.27 (\pm 26.408)	20 (\pm 18.856)		
Gastrointestinal Symptoms: Cycle 24 (n=10,10)	26 (\pm 20.476)	21.33 (\pm 18.539)		
Gastrointestinal Symptoms: Cycle 25 (n=10,8)	24.67 (\pm 19.386)	23.33 (\pm 17.09)		
Gastrointestinal Symptoms: Cycle 26 (n=7,7)	30.48 (\pm 17.152)	20.95 (\pm 15.601)		
Gastrointestinal Symptoms: Cycle 27 (n=6,8)	34.44 (\pm 28.415)	25.83 (\pm 20.912)		
Gastrointestinal Symptoms: Cycle 28 (n=7,8)	28.57 (\pm 23.637)	23.96 (\pm 20.967)		
Gastrointestinal Symptoms: Cycle 29 (n=6,7)	22.22 (\pm 5.443)	28.57 (\pm 17.09)		
Gastrointestinal Symptoms: Cycle 30 (n=5,7)	18.67 (\pm 15.202)	21.9 (\pm 17.518)		
Gastrointestinal Symptoms: Cycle 31 (n=3,7)	24.44 (\pm 26.943)	22.86 (\pm 19.572)		
Gastrointestinal Symptoms: Cycle 32 (n=3,6)	22.22 (\pm 27.756)	27.78 (\pm 19.052)		
Gastrointestinal Symptoms: Cycle 33 (n=3,6)	26.67 (\pm 35.277)	23.33 (\pm 17.256)		
Gastrointestinal Symptoms: Cycle 34 (n=3,6)	20 (\pm 29.059)	28.89 (\pm 15.587)		
Gastrointestinal Symptoms: Cycle 35 (n=2,6)	23.33 (\pm 32.998)	20 (\pm 15.202)		
Gastrointestinal Symptoms: Cycle 36 (n=1,5)	0 (\pm 99999)	17.33 (\pm 15.348)		
Gastrointestinal Symptoms: Cycle 37 (n=1,4)	0 (\pm 99999)	21.67 (\pm 13.744)		
Gastrointestinal Symptoms: Cycle 38 (n=0,4)	99999 (\pm 99999)	27.92 (\pm 20.52)		

Gastrointestinal Symptoms: Cycle 39 (n=1,3)	6.67 (± 99999)	31.11 (± 19.245)		
Gastrointestinal Symptoms: Cycle 40 (n=1,3)	0 (± 99999)	26.67 (± 17.638)		
Gastrointestinal Symptoms: Cycle 41 (n=0,3)	99999 (± 99999)	35.56 (± 21.43)		
Gastrointestinal Symptoms: Cycle 42 (n=0,2)	99999 (± 99999)	33.33 (± 18.856)		
Gastrointestinal Symptoms: Cycle 43 (n=0,1)	99999 (± 99999)	20 (± 99999)		
Gastrointestinal Symptoms:EOT (n=33,29)	23.23 (± 18.568)	18.85 (± 19.766)		
Treatment Related Symptoms: Cycle 1 (n=19,13)	12.57 (± 14.797)	16.24 (± 19.038)		
Treatment Related Symptoms: Cycle 2 (n=56,36)	14.48 (± 11.686)	16.2 (± 14.141)		
Treatment Related Symptoms: Cycle 3 (n=49,39)	15.42 (± 12.28)	17.09 (± 18.574)		
Treatment Related Symptoms: Cycle 4 (n=45,36)	17.53 (± 15.622)	13.89 (± 16.074)		
Treatment Related Symptoms: Cycle 5 (n=45,31)	15.06 (± 11.522)	14.52 (± 15.361)		
Treatment Related Symptoms: Cycle 6 (n=41,30)	15.45 (± 13.293)	15 (± 17.577)		
Treatment Related Symptoms: Cycle 7 (n=37,27)	18.77 (± 16.216)	15.84 (± 17.207)		
Treatment Related Symptoms: Cycle 8 (n=35,24)	20.48 (± 19.93)	14.12 (± 17.87)		
Treatment Related Symptoms: Cycle 9 (n=32,23)	18.23 (± 15.917)	14.01 (± 17.558)		
Treatment Related Symptoms: Cycle 10 (n=33,23)	15.99 (± 15.76)	16.91 (± 17.446)		
Treatment Related Symptoms: Cycle 11 (n=35,24)	16.83 (± 16.196)	15.05 (± 21.453)		
Treatment Related Symptoms: Cycle 12 (n=34,21)	16.01 (± 18.989)	11.11 (± 13.494)		
Treatment Related Symptoms: Cycle 13 (n=32,19)	15.45 (± 12.441)	7.89 (± 8.942)		
Treatment Related Symptoms: Cycle 14 (n=29,19)	13.6 (± 12.386)	11.7 (± 13.968)		
Treatment Related Symptoms: Cycle 15 (n=28,16)	15.48 (± 12.95)	8.68 (± 12.664)		
Treatment Related Symptoms: Cycle 16 (n=25,15)	13.78 (± 13.714)	10.74 (± 14.467)		
Treatment Related Symptoms: Cycle 17 (n=21,15)	14.81 (± 15.941)	7.41 (± 8.572)		
Treatment Related Symptoms: Cycle 18 (n=16,14)	17.71 (± 16.999)	10.71 (± 11.828)		
Treatment Related Symptoms: Cycle 19 (n=10,14)	20 (± 17.013)	12.3 (± 13.287)		
Treatment Related Symptoms: Cycle 20 (n=10,12)	18.33 (± 17.382)	9.72 (± 11.392)		
Treatment Related Symptoms: Cycle 21 (n=11,12)	18.18 (± 18.608)	14.81 (± 14.279)		
Treatment Related Symptoms: Cycle 22 (n=10,11)	24.44 (± 22.253)	12.63 (± 12.691)		
Treatment Related Symptoms: Cycle 23 (n=10,10)	22.22 (± 23.57)	13.89 (± 13.671)		
Treatment Related Symptoms: Cycle 24 (n=9,10)	22.84 (± 24.602)	11.67 (± 13.969)		
Treatment Related Symptoms: Cycle 25 (n=8,8)	21.53 (± 21.504)	15.28 (± 14.164)		

Treatment Related Symptoms: Cycle 26 (n=7,7)	26.19 (± 21.448)	12.7 (± 11.437)		
Treatment Related Symptoms: Cycle 27 (n=6,8)	37.96 (± 16.636)	19.44 (± 18.306)		
Treatment Related Symptoms: Cycle 28 (n=5,8)	35.56 (± 21.009)	17.36 (± 15.555)		
Treatment Related Symptoms: Cycle 29 (n=4,7)	16.67 (± 4.536)	15.87 (± 12.184)		
Treatment Related Symptoms: Cycle 30 (n=3,7)	20.37 (± 3.208)	15.87 (± 14.138)		
Treatment Related Symptoms: Cycle 31 (n=3,7)	22.22 (± 11.111)	20.63 (± 17.484)		
Treatment Related Symptoms: Cycle 32 (n=3,6)	16.67 (± 5.556)	20.37 (± 7.59)		
Treatment Related Symptoms: Cycle 33 (n=3,6)	22.22 (± 11.111)	20.37 (± 7.59)		
Treatment Related Symptoms: Cycle 34 (n=3,6)	27.78 (± 9.623)	20.37 (± 12.989)		
Treatment Related Symptoms: Cycle 35 (n=2,6)	11.11 (± 15.713)	17.59 (± 11.34)		
Treatment Related Symptoms: Cycle 36 (n=1,5)	16.67 (± 99999)	25.56 (± 7.454)		
Treatment Related Symptoms: Cycle 37 (n=1,4)	16.67 (± 99999)	26.39 (± 8.333)		
Treatment Related Symptoms: Cycle 38 (n=0,3)	99999 (± 99999)	22.22 (± 11.111)		
Treatment Related Symptoms: Cycle 39 (n=1,3)	0 (± 99999)	29.63 (± 6.415)		
Treatment Related Symptoms: Cycle 40 (n=1,3)	0 (± 99999)	25.93 (± 6.415)		
Treatment Related Symptoms: Cycle 41 (n=0,3)	99999 (± 99999)	24.07 (± 8.486)		
Treatment Related Symptoms: Cycle 42 (n=0,2)	99999 (± 99999)	27.78 (± 7.857)		
Treatment Related Symptoms: Cycle 43 (n=0,1)	99999 (± 99999)	33.33 (± 99999)		
Treatment Related Symptoms: EOT (n=29,27)	24.33 (± 20.542)	20.78 (± 24.969)		
Social Functioning: Cycle 1 (n=61,44)	35.34 (± 22.907)	31.06 (± 20.132)		
Social Functioning: Cycle 2 (n=57,41)	30.99 (± 21.49)	29.81 (± 22.695)		
Social Functioning: Cycle 3 (n=55,40)	29.49 (± 20.534)	30 (± 25.061)		
Social Functioning: Cycle 4 (n=50,38)	27 (± 19.441)	26.17 (± 22.331)		
Social Functioning: Cycle 5 (n=47,33)	27.9 (± 19.087)	24.24 (± 22.473)		
Social Functioning: Cycle 6 (n=43,31)	25.71 (± 21.138)	28.32 (± 23.101)		
Social Functioning: Cycle 7 (n=39,29)	29.06 (± 20.171)	27.2 (± 26.157)		
Social Functioning: Cycle 8 (n=37,25)	30.63 (± 20.015)	27.11 (± 20.051)		
Social Functioning: Cycle 9 (n=35,26)	29.84 (± 27.715)	23.08 (± 19.607)		
Social Functioning: Cycle 10 (n=35,23)	28.89 (± 22.579)	24.64 (± 24.835)		
Social Functioning: Cycle 11 (n=35,24)	29.21 (± 21.573)	24.07 (± 22.383)		
Social Functioning: Cycle 12 (n=35,22)	28.25 (± 24.454)	23.74 (± 22.562)		

Social Functioning: Cycle 13 (n=34,21)	24.84 (± 23.38)	23.81 (± 23.382)		
Social Functioning: Cycle 14 (n=31,19)	27.96 (± 20.056)	25.73 (± 24.018)		
Social Functioning: Cycle 15 (n=30,17)	28.52 (± 20.149)	28.76 (± 28.07)		
Social Functioning: Cycle 16 (n=27,16)	27.16 (± 20.286)	27.78 (± 23.307)		
Social Functioning: Cycle 17 (n=22,15)	28.79 (± 21.32)	23.7 (± 22.564)		
Social Functioning: Cycle 18 (n=17,14)	29.41 (± 26.04)	26.98 (± 21.666)		
Social Functioning: Cycle 19 (n=12,14)	29.63 (± 25.219)	28.57 (± 22.943)		
Social Functioning: Cycle 20 (n=11,13)	31.82 (± 28.119)	29.06 (± 28.16)		
Social Functioning: Cycle 21 (n=11,12)	35.35 (± 30.151)	24.07 (± 23.13)		
Social Functioning: Cycle 22 (n=11,11)	31.31 (± 28.029)	27.27 (± 24.527)		
Social Functioning: Cycle 23 (n=11,10)	30.3 (± 28.149)	26.67 (± 27.317)		
Social Functioning: Cycle 24 (n=10,10)	38.89 (± 28.328)	24.44 (± 24.456)		
Social Functioning: Cycle 25 (n=10,8)	35.56 (± 27.116)	31.94 (± 26.184)		
Social Functioning: Cycle 26 (n=7,7)	46.03 (± 28.276)	22.22 (± 11.111)		
Social Functioning: Cycle 27 (n=6,8)	51.85 (± 28.689)	33.33 (± 28.483)		
Social Functioning: Cycle 28 (n=7,8)	46.03 (± 33.597)	31.94 (± 29.36)		
Social Functioning: Cycle 29 (n=6,7)	35.19 (± 25.74)	28.57 (± 27.857)		
Social Functioning: Cycle 30 (n=5,7)	35.56 (± 26.527)	30.16 (± 29.893)		
Social Functioning: Cycle 31 (n=3,7)	44.44 (± 22.222)	30.16 (± 29.197)		
Social Functioning: Cycle 32 (n=3,6)	33.33 (± 11.111)	31.48 (± 30.965)		
Social Functioning: Cycle 33 (n=3,6)	40.74 (± 23.13)	40.74 (± 31.164)		
Social Functioning: Cycle 34 (n=3,6)	44.44 (± 22.222)	35.19 (± 29.327)		
Social Functioning: Cycle 35 (n=2,6)	38.89 (± 23.57)	33.33 (± 24.343)		
Social Functioning: Cycle 36 (n=1,5)	22.22 (± 99999)	31.11 (± 27.666)		
Social Functioning: Cycle 37 (n=1,4)	22.22 (± 99999)	30.56 (± 39.933)		
Social Functioning: Cycle 38 (n=0,4)	99999 (± 99999)	41.67 (± 41.944)		
Social Functioning: Cycle 39 (n=1,3)	33.33 (± 99999)	51.85 (± 44.905)		
Social Functioning: Cycle 40 (n=1,3)	11.11 (± 99999)	42.59 (± 36.991)		
Social Functioning: Cycle 41 (n=0,3)	99999 (± 99999)	44.44 (± 40.062)		
Social Functioning: Cycle 42 (n=0,2)	99999 (± 99999)	38.89 (± 39.284)		
Social Functioning: Cycle 43 (n=0,1)	99999 (± 99999)	11.11 (± 99999)		

Social Functioning: EOT (n=33,29)	39.73 (± 25.914)	41.38 (± 26.874)		
Disease Related Worries: Cycle 1 (n=61,43)	49.27 (± 26.381)	42.89 (± 23.108)		
Disease Related Worries: Cycle 2 (n=57,41)	38.01 (± 24.55)	36.04 (± 24.942)		
Disease Related Worries: Cycle 3 (n=55,40)	36.46 (± 23.074)	34.58 (± 23.853)		
Disease Related Worries: Cycle 4 (n=50,38)	31.89 (± 22.075)	33.19 (± 23.904)		
Disease Related Worries: Cycle 5 (n=47,33)	37.12 (± 25.619)	30.64 (± 22.742)		
Disease Related Worries: Cycle 6 (n=43,31)	36.43 (± 25.148)	34.05 (± 25)		
Disease Related Worries: Cycle 7 (n=39,29)	39.32 (± 24.825)	32.18 (± 26.618)		
Disease Related Worries: Cycle 8 (n=37,25)	38.29 (± 25.653)	32 (± 22.753)		
Disease Related Worries: Cycle 9 (n=35,26)	35.71 (± 31.116)	32.05 (± 22.072)		
Disease Related Worries: Cycle 10 (n=35,23)	37.3 (± 26.458)	28.02 (± 26.563)		
Disease Related Worries: Cycle 11 (n=35,24)	35.87 (± 25.292)	27.78 (± 22.7)		
Disease Related Worries: Cycle 12 (n=35,22)	35.56 (± 28.621)	29.29 (± 25.325)		
Disease Related Worries: Cycle 13 (n=34,21)	34.64 (± 27.046)	30.16 (± 24.881)		
Disease Related Worries: Cycle 14 (n=31,19)	32.97 (± 22.312)	31.87 (± 22.055)		
Disease Related Worries: Cycle 15 (n=30,17)	34.44 (± 25.16)	33.66 (± 27.25)		
Disease Related Worries: Cycle 16 (n=27,16)	34.16 (± 25.022)	37.85 (± 23.589)		
Disease Related Worries: Cycle 17 (n=22,15)	29.8 (± 22.059)	34.07 (± 27.043)		
Disease Related Worries: Cycle 18 (n=17,14)	30.07 (± 28.805)	32.14 (± 27.232)		
Disease Related Worries: Cycle 19 (n=12,14)	37.5 (± 29.504)	31.75 (± 28.862)		
Disease Related Worries: Cycle 20 (n=11,13)	40.4 (± 32.687)	29.91 (± 31.877)		
Disease Related Worries: Cycle 21 (n=11,12)	39.9 (± 30.512)	27.78 (± 30.887)		
Disease Related Worries: Cycle 22 (n=11,11)	33.33 (± 31.032)	30.3 (± 34.816)		
Disease Related Worries: Cycle 23 (n=11,10)	36.36 (± 35.168)	26.11 (± 29.403)		
Disease Related Worries: Cycle 24 (n=10,10)	41.11 (± 32.309)	27.78 (± 28.328)		
Disease Related Worries: Cycle 25 (n=10,8)	38.33 (± 32.547)	38.89 (± 31.983)		
Disease Related Worries: Cycle 26 (n=7,7)	42.86 (± 33.597)	31.75 (± 33.597)		
Disease Related Worries: Cycle 27 (n=6,8)	52.78 (± 40.023)	34.72 (± 28.133)		
Disease Related Worries: Cycle 28 (n=7,8)	50.79 (± 38.946)	40.28 (± 39.368)		
Disease Related Worries: Cycle 29 (n=6,7)	37.96 (± 35.21)	38.1 (± 35.635)		
Disease Related Worries: Cycle 30 (n=5,7)	35.56 (± 38.809)	34.92 (± 29.696)		

Disease Related Worries: Cycle 31 (n=3,7)	48.15 (± 46.259)	36.51 (± 32.53)		
Disease Related Worries: Cycle 32 (n=3,6)	25.93 (± 23.13)	37.04 (± 38.276)		
Disease Related Worries: Cycle 33 (n=3,6)	51.85 (± 42.066)	35.19 (± 36.118)		
Disease Related Worries: Cycle 34 (n=3,6)	55.56 (± 40.062)	35.19 (± 36.796)		
Disease Related Worries: Cycle 35 (n=2,6)	16.67 (± 23.57)	35.19 (± 34.006)		
Disease Related Worries: Cycle 36 (n=1,5)	0 (± 99999)	31.11 (± 36.345)		
Disease Related Worries: Cycle 37 (n=1,4)	0 (± 99999)	22.22 (± 31.427)		
Disease Related Worries: Cycle 38 (n=0,4)	99999 (± 99999)	33.33 (± 45.361)		
Disease Related Worries: Cycle 39 (n=1,3)	0 (± 99999)	44.44 (± 50.918)		
Disease Related Worries: Cycle 40 (n=1,3)	0 (± 99999)	37.04 (± 35.717)		
Disease Related Worries: Cycle 41 (n=0,3)	99999 (± 99999)	44.44 (± 50.918)		
Disease Related Worries: Cycle 42 (n=0,2)	99999 (± 99999)	50 (± 54.997)		
Disease Related Worries: Cycle 43 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Disease Related Worries: EOT (n=33,29)	50.84 (± 27.079)	41.38 (± 30.123)		
Muscle/Bone Pain Symptom: Cycle 1 (n=59,44)	13.56 (± 20.64)	13.64 (± 20.734)		
Muscle/Bone Pain Symptom: Cycle 2 (n=57,41)	20.47 (± 24.197)	17.89 (± 23.685)		
Muscle/Bone Pain Symptom: Cycle 3 (n=55,40)	16.36 (± 19.108)	23.33 (± 24.108)		
Muscle/Bone Pain Symptom: Cycle 4 (n=50,38)	16 (± 20.471)	21.93 (± 26.024)		
Muscle/Bone Pain Symptom: Cycle 5 (n=47,33)	17.02 (± 18.221)	22.22 (± 27.217)		
Muscle/Bone Pain Symptom: Cycle 6 (n=43,31)	18.6 (± 20.959)	20.43 (± 23.847)		
Muscle/Bone Pain Symptom: Cycle 7 (n=39,29)	20.51 (± 22.446)	21.84 (± 29.915)		
Muscle/Bone Pain Symptom: Cycle 8 (n=37,25)	20.72 (± 22.705)	20 (± 23.57)		
Muscle/Bone Pain Symptom: Cycle 9 (n=35,26)	16.19 (± 18.737)	20.51 (± 21.243)		
Muscle/Bone Pain Symptom: Cycle 10 (n=35,23)	20 (± 25.82)	24.64 (± 28.81)		
Muscle/Bone Pain Symptom: Cycle 11 (n=35,24)	21.9 (± 25.492)	22.22 (± 25.38)		
Muscle/Bone Pain Symptom: Cycle 12 (n=35,22)	20.95 (± 26.918)	19.7 (± 24.471)		
Muscle/Bone Pain Symptom: Cycle 13 (n=34,21)	20.59 (± 24.638)	23.81 (± 28.172)		
Muscle/Bone Pain Symptom: Cycle 14 (n=31,19)	12.9 (± 22.24)	22.81 (± 27.336)		
Muscle/Bone Pain Symptom: Cycle 15 (n=29,17)	11.49 (± 18.422)	25.49 (± 32.338)		
Muscle/Bone Pain Symptom: Cycle 16 (n=27,16)	19.75 (± 24.909)	16.67 (± 24.343)		
Muscle/Bone Pain Symptom: Cycle 17 (n=22,15)	22.73 (± 25.996)	15.56 (± 24.774)		

Muscle/Bone Pain Symptom: Cycle 18 (n=17,14)	15.69 (± 20.809)	14.29 (± 25.198)		
Muscle/Bone Pain Symptom: Cycle 19 (n=12,14)	25 (± 20.719)	16.67 (± 25.318)		
Muscle/Bone Pain Symptom: Cycle 20 (n=11,13)	27.27 (± 25.025)	12.82 (± 21.681)		
Muscle/Bone Pain Symptom: Cycle 21 (n=11,12)	21.21 (± 22.473)	13.89 (± 22.285)		
Muscle/Bone Pain Symptom: Cycle 22 (n=11,11)	15.15 (± 22.918)	24.24 (± 26.208)		
Muscle/Bone Pain Symptom: Cycle 23 (n=11,10)	21.21 (± 26.968)	23.33 (± 22.498)		
Muscle/Bone Pain Symptom: Cycle 24 (n=10,10)	20 (± 23.307)	30 (± 29.187)		
Muscle/Bone Pain Symptom: Cycle 25 (n=10,8)	23.33 (± 27.442)	33.33 (± 30.861)		
Muscle/Bone Pain Symptom: Cycle 26 (n=7,7)	33.33 (± 27.217)	28.57 (± 29.991)		
Muscle/Bone Pain Symptom: Cycle 27 (n=6,8)	50 (± 18.257)	29.17 (± 27.817)		
Muscle/Bone Pain Symptom: Cycle 28 (n=7,8)	38.1 (± 23.002)	33.33 (± 35.635)		
Muscle/Bone Pain Symptom: Cycle 29 (n=6,7)	22.22 (± 27.217)	33.33 (± 27.217)		
Muscle/Bone Pain Symptom: Cycle 30 (n=5,7)	26.67 (± 27.889)	28.57 (± 35.635)		
Muscle/Bone Pain Symptom: Cycle 31 (n=3,7)	22.22 (± 38.49)	38.1 (± 29.991)		
Muscle/Bone Pain Symptom: Cycle 32 (n=3,6)	22.22 (± 38.49)	38.89 (± 13.608)		
Muscle/Bone Pain Symptom: Cycle 33 (n=3,6)	33.33 (± 33.333)	33.33 (± 29.814)		
Muscle/Bone Pain Symptom: Cycle 34 (n=3,6)	11.11 (± 19.245)	44.44 (± 17.213)		
Muscle/Bone Pain Symptom: Cycle 35 (n=2,6)	33.33 (± 47.14)	38.89 (± 13.608)		
Muscle/Bone Pain Symptom: Cycle 36 (n=1,5)	0 (± 99999)	53.33 (± 18.257)		
Muscle/Bone Pain Symptom: Cycle 37 (n=1,4)	0 (± 99999)	50 (± 19.245)		
Muscle/Bone Pain Symptom: Cycle 38 (n=0,4)	99999 (± 99999)	58.33 (± 16.667)		
Muscle/Bone Pain Symptom: Cycle 39 (n=1,3)	0 (± 99999)	44.44 (± 19.245)		
Muscle/Bone Pain Symptom: Cycle 40 (n=1,3)	33.33 (± 99999)	55.56 (± 19.245)		
Muscle/Bone Pain Symptom: Cycle 41 (n=0,3)	99999 (± 99999)	55.56 (± 19.245)		
Muscle/Bone Pain Symptom: Cycle 42 (n=0,2)	99999 (± 99999)	50 (± 23.57)		
Muscle/Bone Pain Symptom: Cycle 43 (n=0,1)	99999 (± 99999)	66.67 (± 99999)		
Muscle/Bone Pain Symptom: EOT (n=33,29)	25.25 (± 27.677)	26.44 (± 30.052)		
Sexual Function: Cycle 1 (n=34,29)	22.55 (± 31.485)	34.48 (± 35.054)		
Sexual Function: Cycle 2 (n=43,30)	17.83 (± 25.561)	30 (± 30.763)		
Sexual Function: Cycle 3 (n=39,29)	17.95 (± 25.185)	36.78 (± 32.544)		
Sexual Function: Cycle 4 (n=34,27)	18.63 (± 24.878)	22.22 (± 30.662)		

Sexual Function: Cycle 5 (n=32,27)	18.75 (± 25.312)	28.4 (± 35.45)		
Sexual Function: Cycle 6 (n=30,23)	14.44 (± 20.869)	31.88 (± 35.503)		
Sexual Function: Cycle 7 (n=28,23)	19.05 (± 24.727)	30.43 (± 37.488)		
Sexual Function: Cycle 8 (n=26,16)	23.08 (± 27.919)	27.08 (± 27.806)		
Sexual Function: Cycle 9 (n=25,19)	13.33 (± 27.217)	28.07 (± 31.94)		
Sexual Function: Cycle 10 (n=25,16)	17.33 (± 29.059)	27.08 (± 32.702)		
Sexual Function: Cycle 11 (n=25,16)	16 (± 25.676)	20.83 (± 26.874)		
Sexual Function: Cycle 12 (n=26,14)	20.51 (± 29.929)	19.05 (± 25.198)		
Sexual Function: Cycle 13 (n=24,15)	16.67 (± 26.006)	22.22 (± 32.53)		
Sexual Function: Cycle 14 (n=25,14)	20 (± 27.217)	26.19 (± 26.726)		
Sexual Function: Cycle 15 (n=21,12)	17.46 (± 27.119)	19.44 (± 26.432)		
Sexual Function: Cycle 16 (n=19,13)	22.81 (± 33.431)	25.64 (± 27.735)		
Sexual Function: Cycle 17 (n=15,12)	20 (± 27.603)	22.22 (± 25.95)		
Sexual Function: Cycle 18 (n=12,11)	22.22 (± 21.711)	18.18 (± 27.34)		
Sexual Function: Cycle 19 (n=7,10)	19.05 (± 26.227)	20 (± 28.109)		
Sexual Function: Cycle 20 (n=8,10)	25 (± 29.547)	13.33 (± 23.307)		
Sexual Function: Cycle 21 (n=7,9)	23.81 (± 25.198)	14.81 (± 24.216)		
Sexual Function: Cycle 22 (n=8,9)	33.33 (± 30.861)	14.81 (± 24.216)		
Sexual Function: Cycle 23 (n=7,8)	23.81 (± 31.706)	20.83 (± 24.801)		
Sexual Function: Cycle 24 (n=5,8)	26.67 (± 27.889)	16.67 (± 25.198)		
Sexual Function: Cycle 25 (n=5,6)	26.67 (± 36.515)	16.67 (± 27.889)		
Sexual Function: Cycle 26 (n=4,6)	25 (± 31.914)	16.67 (± 27.889)		
Sexual Function: Cycle 27 (n=1,6)	33.33 (± 99999)	16.67 (± 27.889)		
Sexual Function: Cycle 28 (n=3,6)	33.33 (± 33.333)	16.67 (± 27.889)		
Sexual Function: Cycle 29 (n=1,6)	33.33 (± 99999)	16.67 (± 27.889)		
Sexual Function: Cycle 30 (n=1,6)	33.33 (± 99999)	16.67 (± 27.889)		
Sexual Function: Cycle 31 (n=1,6)	33.33 (± 99999)	16.67 (± 27.889)		
Sexual Function: Cycle 32 (n=3,5)	22.22 (± 38.49)	20 (± 29.814)		
Sexual Function: Cycle 33 (n=1,5)	33.33 (± 99999)	20 (± 29.814)		
Sexual Function: Cycle 34 (n=1,5)	33.33 (± 99999)	33.33 (± 33.333)		
Sexual Function: Cycle 35 (n=1,5)	33.33 (± 99999)	20 (± 29.814)		

Sexual Function: Cycle 36 (n=1,4)	0 (± 99999)	25 (± 31.914)		
Sexual Function: Cycle 37 (n=1,3)	0 (± 99999)	33.33 (± 33.333)		
Sexual Function: Cycle 38 (n=0,3)	99999 (± 99999)	33.33 (± 33.333)		
Sexual Function: Cycle 39 (n=1,2)	33.33 (± 99999)	16.67 (± 23.57)		
Sexual Function: Cycle 40 (n=1,2)	66.67 (± 99999)	0 (± 0)		
Sexual Function: Cycle 41 (n=0,2)	99999 (± 99999)	16.67 (± 23.57)		
Sexual Function: Cycle 42 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Sexual Function: Cycle 43 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Sexual Function: EOT (n=22,19)	25.76 (± 27.084)	49.12 (± 37.463)		
Information/Communication: Cycle 1 (n=61,44)	8.74 (± 21.86)	6.82 (± 15.384)		
Information/Communication: Cycle 2 (n=57,41)	5.85 (± 12.791)	5.69 (± 14.724)		
Information/Communication: Cycle 3 (n=55,40)	5.45 (± 14.001)	5 (± 14.222)		
Information/Communication: Cycle 4 (n=50,38)	4.67 (± 11.684)	5.26 (± 12.318)		
Information/Communication: Cycle 5 (n=47,33)	3.55 (± 10.389)	7.07 (± 18.177)		
Information/Communication: Cycle 6 (n=43,31)	4.65 (± 11.687)	5.38 (± 15.146)		
Information/Communication: Cycle 7 (n=39,29)	6.84 (± 13.636)	9.2 (± 23.395)		
Information/Communication: Cycle 8 (n=37,25)	8.11 (± 16.491)	5.33 (± 15.753)		
Information/Communication: Cycle 9 (n=35,26)	5.71 (± 12.746)	3.85 (± 10.86)		
Information/Communication: Cycle 10 (n=35,23)	8.57 (± 16.848)	7.25 (± 17.281)		
Information/Communication: Cycle 11 (n=35,24)	7.62 (± 18.232)	5.56 (± 16.051)		
Information/Communication: Cycle 12 (n=35,22)	10.48 (± 22.537)	1.52 (± 7.107)		
Information/Communication: Cycle 13 (n=34,21)	3.92 (± 10.901)	4.76 (± 11.952)		
Information/Communication: Cycle 14 (n=31,19)	6.45 (± 13.387)	3.51 (± 10.51)		
Information/Communication: Cycle 15 (n=30,17)	4.44 (± 11.525)	7.84 (± 18.743)		
Information/Communication: Cycle 16 (n=27,16)	2.47 (± 8.896)	8.33 (± 14.907)		
Information/Communication: Cycle 17 (n=22,15)	4.55 (± 11.708)	2.22 (± 8.607)		
Information/Communication: Cycle 18 (n=17,14)	7.84 (± 14.575)	7.14 (± 19.298)		
Information/Communication: Cycle 19 (n=12, 14)	0 (± 0)	2.38 (± 8.909)		
Information/Communication: Cycle 20 (n=11,13)	3.03 (± 10.05)	2.56 (± 9.245)		
Information/Communication: Cycle 21 (n=11,12)	6.06 (± 13.484)	2.78 (± 9.623)		
Information/Communication: Cycle 22 (n=11,11)	6.06 (± 13.484)	3.03 (± 10.05)		

Information/Communication: Cycle 23 (n=11,10)	9.09 (± 21.556)	3.33 (± 10.541)		
Information/Communication: Cycle 24 (n=10,10)	10 (± 22.498)	3.33 (± 10.541)		
Information/Communication: Cycle 25 (n=10,8)	6.67 (± 14.055)	4.17 (± 11.785)		
Information/Communication: Cycle 26 (n=6,7)	11.11 (± 17.213)	4.76 (± 12.599)		
Information/Communication: Cycle 27 (n=6,8)	0 (± 0)	4.17 (± 11.785)		
Information/Communication: Cycle 28 (n=7,8)	9.52 (± 16.265)	4.17 (± 11.785)		
Information/Communication: Cycle 29 (n=6,7)	5.56 (± 13.608)	4.76 (± 12.599)		
Information/Communication: Cycle 30 (n=5,7)	0 (± 0)	4.76 (± 12.599)		
Information/Communication: Cycle 31 (n=3,7)	0 (± 0)	4.76 (± 12.599)		
Information/Communication: Cycle 32 (n=3,6)	0 (± 0)	5.56 (± 13.608)		
Information/Communication: Cycle 33 (n=3,6)	11.11 (± 19.245)	0 (± 0)		
Information/Communication: Cycle 34 (n=3,6)	11.11 (± 19.245)	5.56 (± 13.608)		
Information/Communication: Cycle 35 (n=2,6)	0 (± 0)	5.56 (± 13.608)		
Information/Communication: Cycle 36 (n=1,5)	0 (± 99999)	0 (± 0)		
Information/Communication: Cycle 37 (n=1,4)	0 (± 99999)	0 (± 0)		
Information/Communication: Cycle 38 (n=0,4)	99999 (± 99999)	8.33 (± 16.667)		
Information/Communication: Cycle 39 (n=1,3)	0 (± 99999)	11.11 (± 19.245)		
Information/Communication: Cycle 40 (n=1,3)	0 (± 99999)	11.11 (± 19.245)		
Information/Communication: Cycle 41 (n=0,3)	99999 (± 99999)	11.11 (± 19.245)		
Information/Communication: Cycle 42 (n=0,2)	99999 (± 99999)	0 (± 0)		
Information/Communication: Cycle 43 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Information/Communication: EOT (n=33,29)	10.1 (± 19.516)	5.75 (± 20.057)		
Body Image: Cycle 1 (n=60,44)	21.67 (± 32.95)	24.24 (± 24.234)		
Body Image: Cycle 2 (n=57,41)	12.87 (± 19.674)	15.45 (± 25.925)		
Body Image: Cycle 3 (n=52,40)	10.9 (± 21.614)	19.17 (± 31.02)		
Body Image: Cycle 4 (n=49,38)	10.88 (± 17.197)	16.67 (± 24.199)		
Body Image: Cycle 5 (n=46,33)	8.7 (± 17.826)	15.15 (± 25.126)		
Body Image: Cycle 6 (n=42,30)	11.9 (± 21.866)	21.11 (± 29.664)		
Body Image: Cycle 7 (n=38,28)	14.91 (± 25.347)	21.43 (± 31.706)		
Body Image: Cycle 8 (n=37,24)	13.51 (± 24.164)	15.28 (± 24.035)		
Body Image: Cycle 9 (n=35,25)	14.29 (± 28.337)	14.67 (± 23.727)		

Body Image: Cycle 10 (n=34,23)	13.73 (\pm 24.779)	18.84 (\pm 26.258)		
Body Image: Cycle 11 (n=35,24)	12.38 (\pm 19.944)	15.28 (\pm 24.035)		
Body Image: Cycle 12 (n=35,22)	10.48 (\pm 21.038)	9.09 (\pm 23.417)		
Body Image: Cycle 13 (n=34,21)	7.84 (\pm 20.199)	7.94 (\pm 17.965)		
Body Image: Cycle 14 (n=31,19)	12.9 (\pm 23.847)	7.02 (\pm 13.962)		
Body Image: Cycle 15 (n=29,17)	9.2 (\pm 21.633)	9.8 (\pm 19.596)		
Body Image: Cycle 16 (n=27,16)	16.05 (\pm 28.3)	10.42 (\pm 23.472)		
Body Image: Cycle 17 (n=22,15)	12.12 (\pm 26.318)	8.89 (\pm 15.258)		
Body Image: Cycle 18 (n=17,14)	15.69 (\pm 31.441)	7.14 (\pm 14.194)		
Body Image: Cycle 19 (n=12,14)	11.11 (\pm 25.95)	2.38 (\pm 8.909)		
Body Image: Cycle 20 (n=11,12)	9.09 (\pm 30.151)	8.33 (\pm 15.076)		
Body Image: Cycle 21 (n=11,12)	9.09 (\pm 30.151)	2.78 (\pm 9.623)		
Body Image: Cycle 22 (n=11,11)	15.15 (\pm 31.14)	6.06 (\pm 13.484)		
Body Image: Cycle 23 (n=11,10)	9.09 (\pm 21.556)	6.67 (\pm 14.055)		
Body Image: Cycle 24 (n=10,10)	16.67 (\pm 36.004)	3.33 (\pm 10.541)		
Body Image: Cycle 25 (n=10,8)	16.67 (\pm 36.004)	8.33 (\pm 15.43)		
Body Image: Cycle 26 (n=7,7)	23.81 (\pm 41.786)	4.76 (\pm 12.599)		
Body Image: Cycle 27 (n=6,8)	22.22 (\pm 40.369)	4.17 (\pm 11.785)		
Body Image: Cycle 28 (n=6,8)	22.22 (\pm 40.369)	12.5 (\pm 17.252)		
Body Image: Cycle 29 (n=6,7)	11.11 (\pm 27.217)	0 (\pm 0)		
Body Image: Cycle 30 (n=5,7)	0 (\pm 0)	0 (\pm 0)		
Body Image: Cycle 31 (n=3,7)	0 (\pm 0)	0 (\pm 0)		
Body Image: Cycle 32 (n=3,6)	0 (\pm 0)	0 (\pm 0)		
Body Image: Cycle 33 (n=3,6)	0 (\pm 0)	5.56 (\pm 13.608)		
Body Image: Cycle 34 (n=3,6)	22.22 (\pm 38.49)	5.56 (\pm 13.608)		
Body Image: Cycle 35 (n=2,6)	16.67 (\pm 23.57)	11.11 (\pm 17.213)		
Body Image: Cycle 36 (n=1,5)	0 (\pm 99999)	0 (\pm 0)		
Body Image: Cycle 37 (n=1,4)	0 (\pm 99999)	8.33 (\pm 16.667)		
Body Image: Cycle 38 (n=0,4)	99999 (\pm 99999)	8.33 (\pm 16.667)		
Body Image: Cycle 39 (n=1,3)	0 (\pm 99999)	22.22 (\pm 38.49)		
Body Image: Cycle 40 (n=1,3)	0 (\pm 99999)	0 (\pm 0)		
Body Image: Cycle 41 (n=0,3)	99999 (\pm 99999)	11.11 (\pm 19.245)		
Body Image: Cycle 42 (n=0,2)	99999 (\pm 99999)	0 (\pm 0)		

Body Image: Cycle 43 (n=0,1)	99999 (± 99999)	0 (± 99999)		
Body Image: EOT (n=33,29)	23.23 (± 32.792)	18.39 (± 31.605)		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentration of Soluble Protein Biomarker (sKIT)

End point title	Plasma Concentration of Soluble Protein Biomarker (sKIT)
-----------------	--

End point description:

sKIT analysis set included all enrolled subjects who received at least 1 dose of study drug and had at least 1 biomarker parameter from the corresponding assay sample with both a baseline and post-treatment assessment. Here, "99999" for mean and standard deviation signifies data not available (NA) as none of the subjects were evaluable in the given group at specified time point. Here, 'n' signifies those subjects who were evaluable at specified time point for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 1 and 15 of Cycle 1, Day 1 of Cycle 2, 3 and every 2 cycles thereafter (Cycle 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43), End of Treatment (up to 1226 days)

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	45		
Units: picogram per milliliter (pcg/mL)				
arithmetic mean (standard deviation)				
Cycle1/Day1 (n =58, 45)	58218.8 (± 18406.35)	62267.7 (± 17298.53)		
Cycle1/Day15 (n =58, 44)	51614.2 (± 18638.21)	48946.4 (± 15189.15)		
Cycle2/Day1 (n= 56, 44)	37705.1 (± 14128.27)	40334.8 (± 14304.02)		
Cycle3/Day1 (n =52, 41)	26939.9 (± 10839.77)	30224 (± 13709.28)		
Cycle5/Day1 (n= 46, 35)	20596.1 (± 7331.69)	23892.6 (± 11355.85)		
Cycle7/Day1 (n =38, 29)	18222.9 (± 8010.89)	19786.4 (± 10564.09)		
Cycle9/Day1 (n =32, 24)	17677 (± 6179.43)	19761.3 (± 12429.49)		
Cycle11/Day1 (n =33, 23)	16689.8 (± 7452.02)	21091.1 (± 13222.55)		
Cycle13/Day1 (n =30, 20)	16657.7 (± 8876.97)	18103 (± 7763.15)		
Cycle15/Day1 (n =28, 14)	15675 (± 6591.98)	16222.5 (± 4939.29)		
Cycle17/Day1 (n =21, 15)	15705.5 (± 5665.32)	15769 (± 7628.43)		
Cycle19/Day1 (n =12, 13)	14600 (± 4537.41)	15811.2 (± 7297.71)		

Cycle21/Day1 (n =11, 10)	14809.5 (± 4395.74)	15577 (± 5782.28)		
Cycle23/Day1 (n =11, 8)	13332.3 (± 3670.43)	12238.8 (± 4252.01)		
Cycle25/Day1 (n =10, 7)	13674 (± 5440.63)	13112.1 (± 5057.35)		
Cycle27/Day1 (n =5, 8)	12616 (± 3513.31)	16553.1 (± 8092.47)		
Cycle29/Day1 (n =4, 7)	13638.8 (± 3555.38)	16261.4 (± 10057.56)		
Cycle31/Day1 (n =2, 6)	9567.5 (± 1644.02)	10950.8 (± 4149.34)		
Cycle33/Day1 (n =2, 6)	9440 (± 1541.49)	10590 (± 4008.65)		
Cycle35/Day1 (n =1, 6)	11255 (± 99999)	10241.7 (± 2748.91)		
Cycle37/Day1 (n =0, 4)	99999 (± 99999)	9038.8 (± 3243.45)		
Cycle39/Day1 (n =0, 2)	99999 (± 99999)	8672.5 (± 477.3)		
Cycle41/Day1 (n =0, 3)	99999 (± 99999)	7023.3 (± 1849)		
Cycle43/Day1 (n =0, 1)	99999 (± 99999)	9360 (± 99999)		
EOT (n= 30, 28)	21680.3 (± 10358.35)	22605.5 (± 10953)		

Statistical analyses

No statistical analyses for this end point

Secondary: Minimum Observed Plasma Concentration (Ctough) of Sunitinib and its Metabolite SU012662

End point title	Minimum Observed Plasma Concentration (Ctough) of Sunitinib and its Metabolite SU012662
-----------------	---

End point description:

Ctough is the plasma concentration of sunitinib prior to study drug administration (lowest level at which a drug is present in the body). Pharmacokinetic (PK) population included all participants who received at least 1 dose of study medication, had baseline and at least 1 post-baseline value for each parameters. Here, 'n' signifies those subjects who were evaluable at specified time point for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: nanogram per milliliter (ng/mL)				
arithmetic mean (standard deviation)				
Sunitinib: Cycle1/Day15 (n =60, 44)	52.78 (± 27.361)	41.93 (± 21.707)		

Sunitinib: Cycle2/Day1 (n =57, 44)	42.68 (± 20.32)	38.38 (± 22.765)		
Sunitinib: Cycle3/Day1 (n =54, 41)	41.79 (± 21.517)	38.49 (± 18.75)		
Sunitinib: Cycle5/Day1 (n =48, 35)	35.57 (± 15.221)	33.6 (± 15.01)		
SU012662: Cycle1/Day15 (n =60, 44)	18.03 (± 11.169)	14.26 (± 9.264)		
SU012662: Cycle2/Day1 (n =57, 44)	15.94 (± 9.059)	12.53 (± 8)		
SU012662: Cycle3/Day1 (n =54, 41)	15.85 (± 9.444)	13.64 (± 6.983)		
SU012662: Cycle5/Day1 (n =48, 35)	12.78 (± 6.375)	12.61 (± 6.735)		

Statistical analyses

No statistical analyses for this end point

Secondary: Dose-Corrected Trough Plasma Concentration of Sunitinib and its Metabolite SU012662

End point title	Dose-Corrected Trough Plasma Concentration of Sunitinib and its Metabolite SU012662
-----------------	---

End point description:

Dose-corrected plasma trough concentration is calculated as: trough plasma concentration*(intended dose divided by actual dose). Intended dose was defined as the starting dose in the study and actual dose was defined as the last dose which the subject had received over the last 10 consecutive days prior sampling. SU012662 is the metabolite of sunitinib. PK population included all participants who received at least 1 dose of study medication, had baseline and at least 1 post-baseline value for each parameters. Here, 'n' signifies those subjects who were evaluable at specified time point for each arm, respectively.

End point type	Secondary
End point timeframe:	Pre dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: ng/mL				
arithmetic mean (standard deviation)				
Sunitinib: Cycle1/Day15 (n =59, 40)	52.66 (± 27.136)	43.38 (± 21.52)		
Sunitinib: Cycle2/Day1 (n =55, 36)	42.89 (± 20.607)	39.52 (± 19.833)		
Sunitinib: Cycle3/Day1 (n =49, 39)	44.99 (± 23.031)	38.56 (± 18.375)		
Sunitinib: Cycle5/Day1 (n =43, 35)	42.49 (± 16.769)	33.27 (± 16.733)		
SU012662: Cycle1/Day15 (n =59, 40)	18.14 (± 11.059)	14.79 (± 9.436)		

SU012662: Cycle2/Day1 (n =55, 36)	16.01 (± 9.132)	13.09 (± 7.684)		
SU012662: Cycle3/Day1 (n =49, 39)	17.37 (± 10.233)	14.22 (± 7.085)		
SU012662: Cycle5/Day1 (n =43, 35)	15.35 (± 6.882)	12.53 (± 6.914)		

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Curve (AUC24) of Sunitinib and its Metabolite SU012662

End point title	Area Under the Curve (AUC24) of Sunitinib and its Metabolite SU012662
-----------------	---

End point description:

Area under the plasma concentration-time profile from time zero (pre-dose) to 24 hours post-dose. SU012662 is the metabolite of sunitinib.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (0 hour) and at multiple time points (up to 24 hours) post dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5 (each cycle 28 days)

End point values	Sunitinib: Treatment Naïve Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[2]	0 ^[3]		
Units: (nanogram*hour) per milliliter				
arithmetic mean (standard deviation)	()	()		

Notes:

[2] - Data for this secondary endpoint is not available and shall be posted in April 2017.

[3] - Data for this secondary endpoint is not available and shall be posted in April 2017.

Statistical analyses

No statistical analyses for this end point

Secondary: Oral Clearance (CL/F) of Sunitinib and its Metabolite SU012662

End point title	Oral Clearance (CL/F) of Sunitinib and its Metabolite SU012662
-----------------	--

End point description:

Clearance is a quantitative measure of the rate at which a drug substance is removed from the body.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5 (each cycle 28 days)

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[4]	0 ^[5]		
Units: milliliter per minute				
arithmetic mean (standard deviation)	()	()		

Notes:

[4] - Data for this secondary endpoint is not available and shall be posted in April 2017.

[5] - Data for this secondary endpoint is not available and shall be posted in April 2017.

Statistical analyses

No statistical analyses for this end point

Secondary: Half Maximal Effective Concentration (EC50) of Sunitinib

End point title	Half Maximal Effective Concentration (EC50) of Sunitinib
End point description: Concentration of sunitinib in plasma at which 50 percent of the maximum effect was observed.	
End point type	Secondary
End point timeframe: Pre dose on Day 15 of Cycle 1, Day 1 of Cycle 2, 3 and 5 (each cycle 28 days)	

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[6]	0 ^[7]		
Units: milligram per milliliter				
arithmetic mean (standard deviation)	()	()		

Notes:

[6] - Data for this secondary endpoint is not available and shall be posted in April 2017.

[7] - Data for this secondary endpoint is not available and shall be posted in April 2017.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
End point description: An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose (up to Day 1226) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Safety analysis set included all subjects who received at least 1 dose of study medication.	
End point type	Secondary

End point timeframe:
Baseline up to 1226 days

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: subjects				
AEs	59	45		
SAEs	15	11		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
-----------------	---

End point description:

Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 1226 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category. Safety analysis set included all subjects who received at least 1 dose of study medication.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 1226 days

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: subjects				
AEs	57	44		
SAEs	7	3		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Adverse Events (AEs) According to Severity

End point title	Number of Subjects With Adverse Events (AEs) According to Severity
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. AE was assessed according to severity grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events [CTCAE] Version 3.0 Grade 1 =mild; Grade 2 =moderate; within normal limits, Grade 3 =severe or medically significant but not immediately life-threatening; Grade 4 =life-threatening or disabling; urgent intervention indicated; Grade 5 =death. Safety analysis set included all subjects who received at least 1 dose of study medication. Here, "number of subjects analyzed" signifies subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 1226 days

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	59	45		
Units: subjects				
Grade 1	4	6		
Grade 2	12	11		
Grade 3	36	20		
Grade 4	5	6		
Grade 5	2	2		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Clinically Significant Laboratory Abnormalities

End point title	Number of Subjects With Clinically Significant Laboratory Abnormalities
-----------------	---

End point description:

Following parameters were analyzed for laboratory examination: hematology (hemoglobin, red blood cell count, platelet count, white blood cell count, total neutrophils, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine); electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate); urinalysis (urine protein), miscellaneous (pregnancy test, Chromogranin A). Clinically significant laboratory abnormalities were identified by the Investigator.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 1226 days

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: subjects	30	22		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Change From Baseline in Vital Signs Abnormalities

End point title	Number of Subjects With Change From Baseline in Vital Signs Abnormalities
End point description: Criteria for change in vital signs were defined as: ≥ 20 mmHg or ≥ 40 mmHg or ≥ 60 mmHg increase from baseline in systolic blood pressure (SBP); ≥ 10 mmHg or ≥ 20 mmHg or ≥ 30 mmHg increase from baseline in diastolic blood pressure (DBP); increase of ≥ 1.1 degree Celsius in baseline body temperature (temp.). Safety analysis set included all subjects who received at least 1 dose of study medication.	
End point type	Secondary
End point timeframe: Baseline up to 1226 days	

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: subjects				
SBP: increase from baseline ≥ 20	31	23		
SBP: increase from baseline ≥ 40	6	9		
SBP: increase from baseline ≥ 60	3	3		
DBP: increase from baseline ≥ 10	41	35		
DBP: increase from baseline ≥ 20	15	19		
DBP: increase from baseline ≥ 30	6	6		
Temp.: increase from baseline ≥ 1.1 degree Celsius	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Increase From Baseline in Corrected QT Interval (QTc)

End point title	Number of Subjects With Increase From Baseline in Corrected
-----------------	---

End point description:

QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG). QTc is the QT interval corrected for heart rate. QTc was calculated using both the Bazett correction (QTcB) and the Fridericia correction (QTcF). Safety analysis set included all subjects who received at least 1 dose of study medication.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 1226 days

End point values	Sunitinib: Treatment Naïve Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: subjects				
QTcB	0	0		
QTcF	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Change From Baseline in Physical Examinations Findings

End point title	Number of Subjects With Change From Baseline in Physical Examinations Findings
-----------------	--

End point description:

Physical examination included an examination of the general appearance, skin, heart, head, eyes, ears, nose, throat, breasts, abdomen, musculoskeletal, neck, extremities, thyroid and others. Safety analysis set included all subjects who received at least 1 dose of study medication.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 1226 days

End point values	Sunitinib: Treatment Naïve Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: subjects	23	19		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Change From Baseline in Body Weight

End point title	Number of Subjects With Change From Baseline in Body Weight
-----------------	---

End point description:

Subjects with increase of ≥ 5 percent and decrease of ≥ 5 percent from baseline in body weight were reported in this outcome measure. Safety analysis set included all subjects who received at least 1 dose of study medication.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 1226 days

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: subjects				
Increase of ≥ 5 percent	27	9		
Decrease of ≥ 5 percent	18	15		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Eastern Co-operative Oncology Group Performance Status (ECOG-PS)

End point title	Number of Subjects With Eastern Co-operative Oncology Group Performance Status (ECOG-PS)
-----------------	--

End point description:

ECOG-PS is used to assess how disease affects daily living abilities of subject and measured on 6-point scale ranging from 0-5 (0= fully active/able to carry on all pre-disease activities without restriction; 1= restricted in physically strenuous activity but ambulatory/able to carry out light or sedentary work; 2= ambulatory for more than 50% of waking hours and capable of all self-care but unable to carry out any work activities; 3= capable of limited self-care, confined to bed or chair $>50\%$ of waking hours; 4= completely disabled, not capable of any self-care, totally confined to bed or chair; 5= dead. Higher score=greater functional impairment. Only those ECOG-PS categories, in which at least one subject had data at any indicated time point were reported in this outcome measure. Subject with not reported (NR) category did not provided any ECOG performance status. Safety analysis set and 'n' signifies those subjects who were evaluable at specified time point for each arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, End of treatment (up to maximum duration of 1226 days)

End point values	Sunitinib: Treatment Naive Cohort	Sunitinib: Later-Line Cohort		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	45		
Units: subjects				
Cycle 1/Day 1: ECOG-PS =0 (n=61,45)	37	25		
Cycle 1/Day 1: ECOG-PS =1 (n=61,45)	15	14		
Cycle 1/Day 1: ECOG-PS =NR (n=61,45)	9	6		
Cycle 2/Day 1: ECOG-PS =0 (n=59,44)	37	30		
Cycle 2/Day 1: ECOG-PS =1 (n=59,44)	19	13		
Cycle 2/Day 1: ECOG-PS =NR (n=59,44)	3	1		
Cycle 3/Day 1: ECOG-PS =0 (n=56,41)	37	29		
Cycle 3/Day 1: ECOG-PS =1 (n=56,41)	17	10		
Cycle 3/Day 1: ECOG-PS =2 (n=56,41)	0	1		
Cycle 3/Day 1: ECOG-PS =3 (n=56,41)	0	1		
Cycle 3/Day 1: ECOG-PS =NR (n=56,41)	2	0		
Cycle 4/Day 1: ECOG-PS =0 (n=51,39)	34	25		
Cycle 4/Day 1: ECOG-PS =1 (n=51,39)	15	13		
Cycle 4/Day 1: ECOG-PS =NR (n=51,39)	2	1		
Cycle 5/Day 1: ECOG-PS =0 (n=48,35)	34	23		
Cycle 5/Day 1: ECOG-PS =1 (n=48,35)	13	11		
Cycle 5/Day 1: ECOG-PS =2 (n=48,35)	1	1		
Cycle 6/Day 1: ECOG-PS =0 (n=43,31)	30	21		
Cycle 6/Day 1: ECOG-PS =1 (n=43,31)	13	9		
Cycle 6/Day 1: ECOG-PS =2 (n=43,31)	0	1		
Cycle 7/Day 1: ECOG-PS =0 (n=40,29)	27	21		
Cycle 7/Day 1: ECOG-PS =1 (n=40,29)	13	7		
Cycle 7/Day 1: ECOG-PS =2 (n=40,29)	0	1		
Cycle 8/Day 1: ECOG-PS =0 (n=37,26)	24	20		
Cycle 8/Day 1: ECOG-PS =1 (n=37,26)	13	6		
Cycle 9/Day 1: ECOG-PS =0 (n=35,26)	24	20		
Cycle 9/Day 1: ECOG-PS =1 (n=35,26)	11	6		
Cycle 10/Day 1: ECOG-PS =0 (n=35,25)	22	18		
Cycle 10/Day 1: ECOG-PS =1 (n=35,25)	13	6		
Cycle 10/Day 1: ECOG-PS =NR (n=35,25)	0	1		
Cycle 11/Day 1: ECOG-PS =0 (n=35,24)	22	18		
Cycle 11/Day 1: ECOG-PS =1 (n=35,24)	13	6		
Cycle 12/Day 1: ECOG-PS =0 (n=35,22)	22	16		
Cycle 12/Day 1: ECOG-PS =1 (n=35,22)	13	6		
Cycle 13/Day 1: ECOG-PS =0 (n=34,21)	21	15		
Cycle 13/Day 1: ECOG-PS =1 (n=34,21)	13	6		
Cycle 14/Day 1: ECOG-PS =0 (n=31,20)	19	12		

Cycle 14/Day 1: ECOG-PS =1 (n=31,20)	11	6		
Cycle 14/Day 1: ECOG-PS =NR (n=31,20)	1	2		
Cycle 15/Day 1: ECOG-PS =0 (n=30,17)	20	13		
Cycle 15/Day 1: ECOG-PS =1 (n=30,17)	10	4		
Cycle 16/Day 1: ECOG-PS =0 (n=27,16)	16	13		
Cycle 16/Day 1: ECOG-PS =1 (n=27,16)	10	3		
Cycle 16/Day 1: ECOG-PS =NR (n=27,16)	1	0		
Cycle 17/Day 1: ECOG-PS =0 (n=22,15)	15	13		
Cycle 17/Day 1: ECOG-PS =1 (n=22,15)	6	2		
Cycle 17/Day 1: ECOG-PS =NR (n=22,15)	1	0		
Cycle 18/Day 1: ECOG-PS =0 (n=17,14)	10	12		
Cycle 18/Day 1: ECOG-PS =1 (n=17,14)	5	1		
Cycle 18/Day 1: ECOG-PS =NR (n=17,14)	2	1		
Cycle 19/Day 1: ECOG-PS =0 (n=12,14)	8	12		
Cycle 19/Day 1: ECOG-PS =1 (n=12,14)	3	1		
Cycle 19/Day 1: ECOG-PS =2 (n=12,14)	1	0		
Cycle 19/Day 1: ECOG-PS =NR (n=12,14)	0	1		
Cycle 20/Day 1: ECOG-PS =0 (n=12,13)	8	11		
Cycle 20/Day 1: ECOG-PS =1 (n=12,13)	2	1		
Cycle 20/Day 1: ECOG-PS =2 (n=12,13)	1	0		
Cycle 20/Day 1: ECOG-PS =NR (n=12,13)	1	1		
Cycle 21/Day 1: ECOG-PS =0 (n=11,12)	7	9		
Cycle 21/Day 1: ECOG-PS =1 (n=11,12)	4	2		
Cycle 21/Day 1: ECOG-PS =NR (n=11,12)	0	1		
Cycle 22/Day 1: ECOG-PS =0 (n=11,11)	8	8		
Cycle 22/Day 1: ECOG-PS =1 (n=11,11)	3	1		
Cycle 22/Day 1: ECOG-PS =3 (n=11,11)	0	1		
Cycle 22/Day 1: ECOG-PS =NR (n=11,11)	0	1		
Cycle 23/Day 1: ECOG-PS =0 (n=11,10)	8	7		
Cycle 23/Day 1: ECOG-PS =1 (n=11,10)	2	2		
Cycle 23/Day 1: ECOG-PS =NR (n=11,10)	1	1		

Cycle 24/Day 1: ECOG-PS =0 (n=10,10)	9	7		
Cycle 24/Day 1: ECOG-PS =1 (n=10,10)	0	2		
Cycle 24/Day 1: ECOG-PS =2 (n=10,10)	1	0		
Cycle 24/Day 1: ECOG-PS =NR (n=10,10)	0	1		
Cycle 25/Day 1: ECOG-PS =0 (n=10,8)	8	6		
Cycle 25/Day 1: ECOG-PS =1 (n=10,8)	1	1		
Cycle 25/Day 1: ECOG-PS =2 (n=10,8)	1	0		
Cycle 25/Day 1: ECOG-PS =NR (n=10,8)	0	1		
Cycle 26/Day 1: ECOG-PS =0 (n=7,8)	5	7		
Cycle 26/Day 1: ECOG-PS =1 (n=7,8)	1	1		
Cycle 26/Day 1: ECOG-PS =2 (n=7,8)	1	0		
Cycle 27/Day 1: ECOG-PS =0 (n=7,8)	4	7		
Cycle 27/Day 1: ECOG-PS =1 (n=7,8)	1	1		
Cycle 27/Day 1: ECOG-PS =2 (n=7,8)	1	0		
Cycle 27/Day 1: ECOG-PS =NR (n=7,8)	1	0		
Cycle 28/Day 1: ECOG-PS =0 (n=7,8)	5	6		
Cycle 28/Day 1: ECOG-PS =1 (n=7,8)	1	1		
Cycle 28/Day 1: ECOG-PS =2 (n=7,8)	1	0		
Cycle 28/Day 1: ECOG-PS =NR (n=7,8)	0	1		
Cycle 29/Day 1: ECOG-PS =0 (n=6,7)	5	6		
Cycle 29/Day 1: ECOG-PS =1 (n=6,7)	1	0		
Cycle 29/Day 1: ECOG-PS =NR (n=6,7)	0	1		
Cycle 30/Day 1: ECOG-PS =0 (n=5,7)	5	6		
Cycle 30/Day 1: ECOG-PS =NR (n=5,7)	0	1		
Cycle 31/Day 1: ECOG-PS =0 (n=3,7)	2	5		
Cycle 31/Day 1: ECOG-PS =1 (n=3,7)	1	1		
Cycle 31/Day 1: ECOG-PS =NR (n=3,7)	0	1		
Cycle 32/Day 1: ECOG-PS =0 (n=3,6)	3	5		
Cycle 32/Day 1: ECOG-PS =NR (n=3,6)	0	1		
Cycle 33/Day 1: ECOG-PS =0 (n=3,6)	2	4		
Cycle 33/Day 1: ECOG-PS =1 (n=3,6)	1	1		
Cycle 33/Day 1: ECOG-PS =NR (n=3,6)	0	1		
Cycle 34/Day 1: ECOG-PS =0 (n=3,6)	3	4		
Cycle 34/Day 1: ECOG-PS =1 (n=3,6)	0	1		
Cycle 34/Day 1: ECOG-PS =NR (n=3,6)	0	1		
Cycle 35/Day 1: ECOG-PS =0 (n=2,6)	2	4		
Cycle 35/Day 1: ECOG-PS =1 (n=2,6)	0	1		
Cycle 35/Day 1: ECOG-PS =NR (n=2,6)	0	1		
Cycle 36/Day 1: ECOG-PS =0 (n=1,5)	1	3		
Cycle 36/Day 1: ECOG-PS =1 (n=1,5)	0	1		
Cycle 36/Day 1: ECOG-PS =NR (n=1,5)	0	1		
Cycle 37/Day 1: ECOG-PS =0 (n=1,4)	1	2		
Cycle 37/Day 1: ECOG-PS =1 (n=1,4)	0	1		
Cycle 37/Day 1: ECOG-PS =NR (n=1,4)	0	1		
Cycle 38/Day 1: ECOG-PS =0 (n=1,4)	1	3		
Cycle 38/Day 1: ECOG-PS =1 (n=1,4)	0	1		
Cycle 39/Day 1: ECOG-PS =0 (n=1,3)	1	1		
Cycle 39/Day 1: ECOG-PS =1 (n=1,3)	0	2		

Cycle 40/Day 1: ECOG-PS =0 (n=1,3)	0	1		
Cycle 40/Day 1: ECOG-PS =1 (n=1,3)	1	2		
Cycle 41/Day 1: ECOG-PS =0 (n=0,3)	0	1		
Cycle 41/Day 1: ECOG-PS =1 (n=0,3)	0	1		
Cycle 41/Day 1: ECOG-PS =NR (n=0,3)	0	1		
Cycle 42/Day 1: ECOG-PS =1 (n=0,2)	0	2		
Cycle 43/Day 1: ECOG-PS =1 (n=0,1)	0	1		
EOT: ECOG-PS =0 (n=43,38)	20	14		
EOT: ECOG-PS =1 (n=43,38)	13	12		
EOT: ECOG-PS =2 (n=43,38)	0	4		
EOT: ECOG-PS =3 (n=43,38)	1	1		
EOT: ECOG-PS =NR (n=43,38)	9	7		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to 1226 days

Adverse event reporting additional description:

The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	Sunitinib: Later-Line Cohort
-----------------------	------------------------------

Reporting group description:

Sunitinib 37.5 mg capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in previously treated/late-line participants (participants who developed progressive disease on or after prior systemic therapy).

Reporting group title	Sunitinib: Treatment Naive Cohort
-----------------------	-----------------------------------

Reporting group description:

Sunitinib 37.5 milligram (mg) capsule, orally once daily in each 28-day treatment cycle (up to a maximum of 43 cycles) until death, unacceptable toxicity, consent withdrawal or final analysis in treatment-naïve participants.

Serious adverse events	Sunitinib: Later-Line Cohort	Sunitinib: Treatment Naive Cohort	
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 45 (24.44%)	15 / 61 (24.59%)	
number of deaths (all causes)	2	3	
number of deaths resulting from adverse events			
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			

subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Disease progression			
subjects affected / exposed	2 / 45 (4.44%)	2 / 61 (3.28%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	3 / 45 (6.67%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal stenosis			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			

subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-alcoholic steatohepatitis			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infections and infestations			
Abdominal abscess			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Urosepsis			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	2 / 45 (4.44%)	0 / 61 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Sunitinib: Later-Line Cohort	Sunitinib: Treatment Naive Cohort	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	45 / 45 (100.00%)	59 / 61 (96.72%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Paraneoplastic syndrome			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences (all)	1	1	
Flushing			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	3	
Haemorrhage			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	2	
Hot flush			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Hypertension			
subjects affected / exposed	11 / 45 (24.44%)	16 / 61 (26.23%)	
occurrences (all)	23	30	
Surgical and medical procedures			
Hospitalisation			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	7 / 45 (15.56%)	10 / 61 (16.39%)
occurrences (all)	27	22
Chest pain		
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	2
Discomfort		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Face oedema		
subjects affected / exposed	1 / 45 (2.22%)	3 / 61 (4.92%)
occurrences (all)	1	4
Facial pain		
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	2
Fatigue		
subjects affected / exposed	14 / 45 (31.11%)	19 / 61 (31.15%)
occurrences (all)	20	35
Feeling cold		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Gait disturbance		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	2	0
General physical health deterioration		
subjects affected / exposed	2 / 45 (4.44%)	0 / 61 (0.00%)
occurrences (all)	2	0
Hyperpyrexia		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Influenza like illness		
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)
occurrences (all)	1	1
Malaise		
subjects affected / exposed	1 / 45 (2.22%)	2 / 61 (3.28%)
occurrences (all)	1	4
Mucosal inflammation		

subjects affected / exposed	5 / 45 (11.11%)	6 / 61 (9.84%)	
occurrences (all)	8	6	
Mucous membrane disorder			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Oedema			
subjects affected / exposed	2 / 45 (4.44%)	5 / 61 (8.20%)	
occurrences (all)	2	6	
Oedema peripheral			
subjects affected / exposed	2 / 45 (4.44%)	4 / 61 (6.56%)	
occurrences (all)	2	6	
Pain			
subjects affected / exposed	3 / 45 (6.67%)	1 / 61 (1.64%)	
occurrences (all)	4	1	
Pyrexia			
subjects affected / exposed	8 / 45 (17.78%)	6 / 61 (9.84%)	
occurrences (all)	11	7	
Immune system disorders			
Contrast media allergy			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Hypersensitivity			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	2	
Reproductive system and breast disorders			
Genital erythema			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Menstruation irregular			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Penile erythema			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	4	0	
Perineal pain			

subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Vaginal haemorrhage			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Vaginal inflammation			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	6	
Respiratory, thoracic and mediastinal disorders			
Choking			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Cough			
subjects affected / exposed	6 / 45 (13.33%)	2 / 61 (3.28%)	
occurrences (all)	8	2	
Dysphonia			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Dyspnoea			
subjects affected / exposed	4 / 45 (8.89%)	2 / 61 (3.28%)	
occurrences (all)	6	5	
Dyspnoea exertional			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Epistaxis			
subjects affected / exposed	5 / 45 (11.11%)	7 / 61 (11.48%)	
occurrences (all)	5	13	
Haemoptysis			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	3	
Nasal disorder			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Nasal septum ulceration			

subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	2	0	
Oropharyngeal pain			
subjects affected / exposed	4 / 45 (8.89%)	4 / 61 (6.56%)	
occurrences (all)	7	4	
Productive cough			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Rhinitis allergic			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Upper respiratory tract congestion			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 45 (4.44%)	2 / 61 (3.28%)	
occurrences (all)	3	2	
Depressed mood			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences (all)	1	1	
Hallucination			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Insomnia			
subjects affected / exposed	3 / 45 (6.67%)	0 / 61 (0.00%)	
occurrences (all)	4	0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	9 / 45 (20.00%)	2 / 61 (3.28%)	
occurrences (all)	11	5	
Aspartate aminotransferase increased			
subjects affected / exposed	7 / 45 (15.56%)	4 / 61 (6.56%)	
occurrences (all)	13	8	
Blood alkaline phosphatase increased			

subjects affected / exposed	2 / 45 (4.44%)	1 / 61 (1.64%)
occurrences (all)	2	4
Blood bilirubin increased		
subjects affected / exposed	2 / 45 (4.44%)	1 / 61 (1.64%)
occurrences (all)	2	2
Blood chloride decreased		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Blood chromogranin A increased		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Blood creatinine increased		
subjects affected / exposed	3 / 45 (6.67%)	1 / 61 (1.64%)
occurrences (all)	4	1
Blood folate decreased		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Blood glucose increased		
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	2
Blood iron decreased		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Blood lactate dehydrogenase increased		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Blood phosphorus decreased		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Blood potassium decreased		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	3
Blood pressure increased		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0

Blood thyroid stimulating hormone abnormal			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Blood thyroid stimulating hormone increased			
subjects affected / exposed	2 / 45 (4.44%)	4 / 61 (6.56%)	
occurrences (all)	2	4	
Blood triglycerides increased			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Blood urine present			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	3	
C-reactive protein increased			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Ejection fraction decreased			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Electrocardiogram T wave abnormal			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	3	
Electrocardiogram abnormal			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 45 (2.22%)	2 / 61 (3.28%)	
occurrences (all)	1	4	
Glomerular filtration rate decreased			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Haemoglobin decreased			
subjects affected / exposed	0 / 45 (0.00%)	5 / 61 (8.20%)	
occurrences (all)	0	21	
Neutrophil count			

subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Neutrophil count decreased		
subjects affected / exposed	1 / 45 (2.22%)	4 / 61 (6.56%)
occurrences (all)	1	42
Occult blood positive		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Platelet count decreased		
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	15
Protein urine		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	2
Protein urine present		
subjects affected / exposed	3 / 45 (6.67%)	1 / 61 (1.64%)
occurrences (all)	6	1
Red blood cell count decreased		
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)
occurrences (all)	2	1
Red blood cells urine positive		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Thyroxine free decreased		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Transaminases increased		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Tri-iodothyronine decreased		
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	2
Tri-iodothyronine free decreased		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Urinary sediment present		

subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Urobilinogen urine increased			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Vitamin B12 decreased			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Weight decreased			
subjects affected / exposed	7 / 45 (15.56%)	8 / 61 (13.11%)	
occurrences (all)	8	10	
Weight increased			
subjects affected / exposed	2 / 45 (4.44%)	5 / 61 (8.20%)	
occurrences (all)	6	5	
White blood cell count			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	2	
White blood cell count decreased			
subjects affected / exposed	0 / 45 (0.00%)	6 / 61 (9.84%)	
occurrences (all)	0	35	
White blood cells urine positive			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	2	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Fall			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Limb injury			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	2	
Overdose			

subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Skin abrasion			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Skin wound			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Sunburn			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Tooth fracture			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Wound			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Cardiac disorders			
Cardiac failure			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Cardiovascular symptom			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Palpitations			
subjects affected / exposed	2 / 45 (4.44%)	1 / 61 (1.64%)	
occurrences (all)	2	1	
Nodal arrhythmia			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Ventricular extrasystoles			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Tachycardia			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	3	

Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Cognitive disorder			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Dizziness			
subjects affected / exposed	7 / 45 (15.56%)	3 / 61 (4.92%)	
occurrences (all)	9	4	
Dysaesthesia			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Dysgeusia			
subjects affected / exposed	11 / 45 (24.44%)	14 / 61 (22.95%)	
occurrences (all)	15	21	
Headache			
subjects affected / exposed	9 / 45 (20.00%)	12 / 61 (19.67%)	
occurrences (all)	19	17	
Hyperaesthesia			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	2	0	
Hypogeusia			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	4	
Memory impairment			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Neuropathy peripheral			
subjects affected / exposed	2 / 45 (4.44%)	1 / 61 (1.64%)	
occurrences (all)	2	1	
Neurotoxicity			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	2	0	
Paraesthesia			

subjects affected / exposed	0 / 45 (0.00%)	3 / 61 (4.92%)	
occurrences (all)	0	3	
Polyneuropathy			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	21 / 45 (46.67%)	25 / 61 (40.98%)	
occurrences (all)	99	127	
Anaemia			
subjects affected / exposed	6 / 45 (13.33%)	8 / 61 (13.11%)	
occurrences (all)	24	12	
Lymphopenia			
subjects affected / exposed	3 / 45 (6.67%)	3 / 61 (4.92%)	
occurrences (all)	8	7	
Neutropenia			
subjects affected / exposed	22 / 45 (48.89%)	37 / 61 (60.66%)	
occurrences (all)	109	209	
Thrombocytopenia			
subjects affected / exposed	14 / 45 (31.11%)	18 / 61 (29.51%)	
occurrences (all)	28	63	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	2	
Eye disorders			
Cataract			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences (all)	1	1	
Dry eye			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	5	0	
Eye haemorrhage			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Eyelid bleeding			

subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	2	0	
Eyelid disorder			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Eyelid oedema			
subjects affected / exposed	1 / 45 (2.22%)	2 / 61 (3.28%)	
occurrences (all)	1	2	
Keratitis			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Lacrimation increased			
subjects affected / exposed	0 / 45 (0.00%)	3 / 61 (4.92%)	
occurrences (all)	0	3	
Ocular icterus			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Periorbital oedema			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences (all)	4	1	
Retinal vascular disorder			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Vision blurred			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	3	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	2 / 45 (4.44%)	1 / 61 (1.64%)	
occurrences (all)	3	1	
Abdominal distension			
subjects affected / exposed	3 / 45 (6.67%)	4 / 61 (6.56%)	
occurrences (all)	3	4	
Abdominal pain			
subjects affected / exposed	8 / 45 (17.78%)	15 / 61 (24.59%)	
occurrences (all)	14	20	

Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1
Abdominal pain upper subjects affected / exposed occurrences (all)	7 / 45 (15.56%) 13	5 / 61 (8.20%) 6
Abdominal tenderness subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1
Anal inflammation subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 9	1 / 61 (1.64%) 3
Aphthous ulcer subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	2 / 61 (3.28%) 4
Ascites subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	0 / 61 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	7 / 45 (15.56%) 7	3 / 61 (4.92%) 3
Diarrhoea subjects affected / exposed occurrences (all)	22 / 45 (48.89%) 86	32 / 61 (52.46%) 96
Dry mouth subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	2 / 61 (3.28%) 2
Duodenal stenosis subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1
Dyspepsia subjects affected / exposed occurrences (all)	14 / 45 (31.11%) 21	7 / 61 (11.48%) 12
Dysphagia subjects affected / exposed occurrences (all)	3 / 45 (6.67%) 4	2 / 61 (3.28%) 2

Epigastric discomfort		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Eructation		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Flatulence		
subjects affected / exposed	1 / 45 (2.22%)	3 / 61 (4.92%)
occurrences (all)	3	4
Frequent bowel movements		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Gastritis		
subjects affected / exposed	2 / 45 (4.44%)	1 / 61 (1.64%)
occurrences (all)	2	1
Gastrooesophageal reflux disease		
subjects affected / exposed	4 / 45 (8.89%)	4 / 61 (6.56%)
occurrences (all)	4	5
Gingival bleeding		
subjects affected / exposed	0 / 45 (0.00%)	3 / 61 (4.92%)
occurrences (all)	0	4
Gingival pain		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Gingival swelling		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Glossodynia		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Haemorrhoids		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Hyperchlorhydria		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1

Lip dry		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Melaena		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Mouth ulceration		
subjects affected / exposed	5 / 45 (11.11%)	4 / 61 (6.56%)
occurrences (all)	6	4
Nausea		
subjects affected / exposed	14 / 45 (31.11%)	11 / 61 (18.03%)
occurrences (all)	33	20
Oral dysaesthesia		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Oral mucosal blistering		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Oral pain		
subjects affected / exposed	3 / 45 (6.67%)	1 / 61 (1.64%)
occurrences (all)	4	1
Pancreatitis		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Periodontal disease		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Proctalgia		
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)
occurrences (all)	1	1
Proctitis		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Rectal haemorrhage		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1

Regurgitation			
subjects affected / exposed	0 / 45 (0.00%)	3 / 61 (4.92%)	
occurrences (all)	0	3	
Salivary hypersecretion			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Stomatitis			
subjects affected / exposed	6 / 45 (13.33%)	13 / 61 (21.31%)	
occurrences (all)	22	27	
Toothache			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	3	0	
Vomiting			
subjects affected / exposed	10 / 45 (22.22%)	8 / 61 (13.11%)	
occurrences (all)	14	17	
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Cholelithiasis			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Hepatic function abnormal			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	2	
Hepatomegaly			
subjects affected / exposed	2 / 45 (4.44%)	0 / 61 (0.00%)	
occurrences (all)	2	0	
Hyperbilirubinaemia			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences (all)	1	7	
Hypertransaminasaemia			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Jaundice			

subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	2	
Liver injury			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	2	
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Alopecia			
subjects affected / exposed	1 / 45 (2.22%)	7 / 61 (11.48%)	
occurrences (all)	1	8	
Blister			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Cold sweat			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Dermatitis			
subjects affected / exposed	2 / 45 (4.44%)	2 / 61 (3.28%)	
occurrences (all)	3	2	
Dry skin			
subjects affected / exposed	2 / 45 (4.44%)	4 / 61 (6.56%)	
occurrences (all)	2	4	
Eczema			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Erythema			
subjects affected / exposed	4 / 45 (8.89%)	0 / 61 (0.00%)	
occurrences (all)	4	0	
Haemorrhage subcutaneous			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Hair colour changes			
subjects affected / exposed	6 / 45 (13.33%)	0 / 61 (0.00%)	
occurrences (all)	6	0	

Hyperhidrosis		
subjects affected / exposed	2 / 45 (4.44%)	1 / 61 (1.64%)
occurrences (all)	4	1
Hyperkeratosis		
subjects affected / exposed	1 / 45 (2.22%)	5 / 61 (8.20%)
occurrences (all)	1	9
Macule		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Madarosis		
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	2
Nail discolouration		
subjects affected / exposed	0 / 45 (0.00%)	3 / 61 (4.92%)
occurrences (all)	0	3
Nail disorder		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Night sweats		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Onycholysis		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Palmar-plantar erythrodysesthesia syndrome		
subjects affected / exposed	14 / 45 (31.11%)	19 / 61 (31.15%)
occurrences (all)	33	101
Pigmentation disorder		
subjects affected / exposed	1 / 45 (2.22%)	5 / 61 (8.20%)
occurrences (all)	1	6
Pruritus		
subjects affected / exposed	4 / 45 (8.89%)	1 / 61 (1.64%)
occurrences (all)	5	1
Rash		

subjects affected / exposed	3 / 45 (6.67%)	7 / 61 (11.48%)	
occurrences (all)	4	15	
Skin discolouration			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences (all)	1	1	
Skin disorder			
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)	
occurrences (all)	0	3	
Skin exfoliation			
subjects affected / exposed	1 / 45 (2.22%)	8 / 61 (13.11%)	
occurrences (all)	1	9	
Skin fissures			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Skin hyperpigmentation			
subjects affected / exposed	2 / 45 (4.44%)	2 / 61 (3.28%)	
occurrences (all)	2	2	
Skin hypopigmentation			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Skin lesion			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences (all)	1	1	
Skin toxicity			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Swelling face			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences (all)	1	1	
Vitiligo			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Yellow skin			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Renal and urinary disorders			

Chronic kidney disease subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1	
Dysuria subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1	
Glycosuria subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 61 (0.00%) 0	
Haematuria subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 5	0 / 61 (0.00%) 0	
Nephrolithiasis subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	2 / 61 (3.28%) 2	
Proteinuria subjects affected / exposed occurrences (all)	6 / 45 (13.33%) 12	4 / 61 (6.56%) 4	
Renal colic subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1	
Renal disorder subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1	
Renal failure subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 61 (0.00%) 0	
Endocrine disorders			
Goitre subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1	
Hypothyroidism subjects affected / exposed occurrences (all)	3 / 45 (6.67%) 8	5 / 61 (8.20%) 6	
Thyroid disorder			

subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	4 / 45 (8.89%)	4 / 61 (6.56%)	
occurrences (all)	9	9	
Back pain			
subjects affected / exposed	6 / 45 (13.33%)	2 / 61 (3.28%)	
occurrences (all)	6	2	
Arthritis			
subjects affected / exposed	1 / 45 (2.22%)	2 / 61 (3.28%)	
occurrences (all)	1	2	
Flank pain			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Joint effusion			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Joint swelling			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Limb discomfort			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Muscle spasms			
subjects affected / exposed	3 / 45 (6.67%)	3 / 61 (4.92%)	
occurrences (all)	5	8	
Muscular weakness			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Musculoskeletal pain			

subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Myalgia			
subjects affected / exposed	7 / 45 (15.56%)	2 / 61 (3.28%)	
occurrences (all)	15	2	
Myalgia intercostal			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Neck pain			
subjects affected / exposed	2 / 45 (4.44%)	0 / 61 (0.00%)	
occurrences (all)	2	0	
Osteonecrosis			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	1	0	
Pain in extremity			
subjects affected / exposed	2 / 45 (4.44%)	6 / 61 (9.84%)	
occurrences (all)	2	10	
Spinal osteoarthritis			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Spinal pain			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	2	0	
Infections and infestations			
Abdominal infection			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	2	0	
Bronchitis			
subjects affected / exposed	2 / 45 (4.44%)	1 / 61 (1.64%)	
occurrences (all)	2	1	
Conjunctivitis			
subjects affected / exposed	2 / 45 (4.44%)	1 / 61 (1.64%)	
occurrences (all)	4	1	
Cystitis			
subjects affected / exposed	1 / 45 (2.22%)	2 / 61 (3.28%)	
occurrences (all)	1	2	

Enterocolitis infectious		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Fungal oesophagitis		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Furuncle		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Gastroenteritis		
subjects affected / exposed	2 / 45 (4.44%)	0 / 61 (0.00%)
occurrences (all)	2	0
Gastroenteritis viral		
subjects affected / exposed	2 / 45 (4.44%)	0 / 61 (0.00%)
occurrences (all)	3	0
Gingival abscess		
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	2
Gingivitis		
subjects affected / exposed	1 / 45 (2.22%)	2 / 61 (3.28%)
occurrences (all)	2	2
Hepatitis B		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Herpes zoster		
subjects affected / exposed	0 / 45 (0.00%)	2 / 61 (3.28%)
occurrences (all)	0	2
Influenza		
subjects affected / exposed	3 / 45 (6.67%)	1 / 61 (1.64%)
occurrences (all)	8	3
Lung infection		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Nasopharyngitis		
subjects affected / exposed	2 / 45 (4.44%)	6 / 61 (9.84%)
occurrences (all)	2	11

Oral candidiasis		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Oral herpes		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Parainfluenzae virus infection		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Paronychia		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	2
Pharyngitis		
subjects affected / exposed	1 / 45 (2.22%)	2 / 61 (3.28%)
occurrences (all)	1	3
Pneumonia		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Pulpitis dental		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Sinusitis		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Subcutaneous abscess		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Tinea versicolour		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	2	0
Tonsillitis		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Tooth abscess		
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)
occurrences (all)	1	1

Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 3	2 / 61 (3.28%) 4	
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	6 / 61 (9.84%) 7	
Viral infection subjects affected / exposed occurrences (all)	2 / 45 (4.44%) 2	1 / 61 (1.64%) 1	
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	7 / 45 (15.56%) 7	7 / 61 (11.48%) 20	
Dehydration subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	1 / 61 (1.64%) 1	
Diabetes mellitus subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	2 / 61 (3.28%) 2	
Glucose tolerance impaired subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 61 (0.00%) 0	
Hypercalcaemia subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	1 / 61 (1.64%) 8	
Hyperchloraemia subjects affected / exposed occurrences (all)	0 / 45 (0.00%) 0	1 / 61 (1.64%) 1	
Hypercholesterolaemia subjects affected / exposed occurrences (all)	1 / 45 (2.22%) 1	0 / 61 (0.00%) 0	
Hypercreatininaemia			

subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Hyperglycaemia		
subjects affected / exposed	1 / 45 (2.22%)	3 / 61 (4.92%)
occurrences (all)	1	6
Hyperkalaemia		
subjects affected / exposed	2 / 45 (4.44%)	0 / 61 (0.00%)
occurrences (all)	3	0
Hypermagnesaemia		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	1	0
Hypernatraemia		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Hypertriglyceridaemia		
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)
occurrences (all)	3	0
Hyperuricaemia		
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)
occurrences (all)	0	1
Hypocalcaemia		
subjects affected / exposed	6 / 45 (13.33%)	2 / 61 (3.28%)
occurrences (all)	10	3
Hypochloraemia		
subjects affected / exposed	1 / 45 (2.22%)	2 / 61 (3.28%)
occurrences (all)	1	2
Hypoglycaemia		
subjects affected / exposed	3 / 45 (6.67%)	2 / 61 (3.28%)
occurrences (all)	5	3
Hypokalaemia		
subjects affected / exposed	4 / 45 (8.89%)	6 / 61 (9.84%)
occurrences (all)	7	10
Hypomagnesaemia		
subjects affected / exposed	4 / 45 (8.89%)	5 / 61 (8.20%)
occurrences (all)	6	6
Hypophosphataemia		

subjects affected / exposed	7 / 45 (15.56%)	2 / 61 (3.28%)	
occurrences (all)	9	5	
Hyponatraemia			
subjects affected / exposed	2 / 45 (4.44%)	2 / 61 (3.28%)	
occurrences (all)	2	2	
Hypoproteinaemia			
subjects affected / exposed	1 / 45 (2.22%)	0 / 61 (0.00%)	
occurrences (all)	2	0	
Iron deficiency			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Magnesium deficiency			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Malnutrition			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	
Vitamin B12 deficiency			
subjects affected / exposed	1 / 45 (2.22%)	1 / 61 (1.64%)	
occurrences (all)	1	1	
Vitamin D deficiency			
subjects affected / exposed	0 / 45 (0.00%)	1 / 61 (1.64%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported